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I.     PREFACE 
Woe to that child which when kissed on the forehead tastes salty. He is 
bewitched and soon must die. This is a European adage folklore that 
makes an early reference to the common genetic disease today recognized 
as cystic fibrosis. 
 
Cystic fibrosis (CF), also called mucoviscidosis, is one of the most lethal, 
however fortunately also the most thoroughly understood genetic diseases 
(1), which affects approximately 30,000 children and adults in United 
States (2). The disease was given its name by the first major contributor to 
the understanding of CF in 1938, Dorothy H. Anderson of Columbia 
University. She first called it cystic fibrosis of the pancreas, based on 
the features she observed in pancreatic tissue from autopsies on infants 
and children (3).  
 
While significant medical advances have been made over the ensuing 
years, there is still no cure for this disease, and treatment is only to 
alleviate the symptoms, and directed against the organs affected. The 
primary cause of death is cardiorespiratory failure caused by chronic lung 
infections and inflammation that finally destroys the airway. During the 
1980s the fundamental physiologic defect was clearly established as the 
failure of cyclic-adenomonophosphate (cAMP) regulation of chloride 
transport caused by mutations on the Cystic Fibrosis transmembrane 
conductance regulator (CFTR) (4). 
 
The survival age of patients has with new therapeutic strategies increased  
3-fold from 1960 up until today, with a mean age of approximately 30 
years (4). One significant pharmacological advance was the development 
of pancreatic supplements of enzymes, which resulted in an eradication of 
malnutrition as the principle cause of death (4).  
 
Subsequent to the discovery of the CF gene in 1989, the pace of CF 
research has greatly accelerated. There are many new treatments under 
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investigation, and the most interesting one is gene therapy. If it is possible 
to effectively transfer a recombinant human CFTR gene into the affected 
cells, resulting in production of normal CFTR, there is hope that this 
therapy can be curative (5). The current problem is identification of a 
suitable vector to transfer the gene into the cells. Until such time that this 
hurdle can be surpassed, pharmacological management aimed at 
alleviating the symptoms of this disease will continue to be the mainstay 
of treatment. 
 
In this thesis I describe a strategy for optimizing administration of a β-
lactam antibiotic, cefepime, in treatment of CF patients. This is done by 
investigating both the stability and the antimicrobial effect of cefepime 
during continuous infusion (CI). In addition the pharmacokinetics (PK) of 
cefepime was assessed and pharmacodynamics (PD) of CI were compared 
with traditional intermittent administration. The experiments described 
were done during a stay at the University of Southern California School 
of Pharmacy, USA, in the time period October 2001- September 2002.  
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II.   ABBREVIATIONS
 
ABX  Antibacterial 
AIC  Akaike information criterion 
ATP  Adenosidtriphosphate 
ALT  Alanine aminotransferase 
AST  Aspertate aminotransferase 
BMI  Body Mass Index (weigh in kg/height in meters2) 
cAMP  Cyclic Adenomonophosphate 
CF  Cystic fibrosis 
CFP  Cefepime 
CFU/g  Colonies forming units per gram 
CFTR  Cystic Fibrosis Transmembrane conductance Regulator 
CI  Continuous Infusion 
CLCR  Creatinine Clearance 
CLd  Distribution clearance 
CLt  Total clearance  
D5W  Dextrose 5% in distilled Water 
DNA  Deoxyribonucleotide acid 
ELISA  Enzyme linked immunosorbent assay  
FEV1  Forced expiratory volume within 1 second  
GEN-IC Generalized information criterion  
HPLC  High Pressure Liquid Chromatography  
IL-8  Interleukin-8 
IV  Intravenous 
LPS  Lipid-polysaccharide 
MAP  Maximum a posteriori 
MBC  Minimal Bactericidal Concentration 
MIC  Minimal Inhibitory Concentration 
MS  Mass spectrometry 
MW  Molecular weight, in Dalton 
NCCLS National Committee for Clinical Laboratory Standards 
PAE  Post antibiotic effect 
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PD  Pharmacodynamic 
PIP  Portable Infusion Pump 
PK  Pharmacokinetic 
R(t)  Rate of drug infusion  
TBW  Total Body Weight 
TMB  Tetramethylbenzidine 
Vc  Volume of central compartment 
Vp  Volume of peripheral compartment 
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1. PHARMACOKINETICS AND PHARMACODYNAMICS OF 
CONTINUOUS INFUSION OF CEFEPIME IN CYSTIC 
FIBROSIS PATIENTS, AND STABILITY OF CEFEPIME 
DURING SIMULATED CONTINUOUS INFUSION 
 
1.1 Abstract 
 
Time above minimal inhibitory concentration (MIC) (T>MIC) is the 
PK/PD parameter that best correlates with bacterial killing for cefepime. 
Cefepime CI provides an efficient method of achieving T>MIC 
throughout the dosing interval. The purpose of this study was to 
determine whether cefepime exhibits sufficient stability and antibacterial 
activity to be given by 24-hour CI using portable infusion pumps. In 
addition, assess the PK and PD of CI versus intermittent infusion of 
cefepime in cystic fibrosis patients administered during an acute 
pulmonary exacerbation.  
 
The stability of cefepime in 5% dextrose distilled water (D5W) solutions 
was determined for a simulated CI using a portable infusion pump 
(Microject 30, Sorensen Medical) worn over a period of 24-36 hours. The 
temperatures in the bags were measured every ½ hour. In addition the 
stability at different storage conditions was tested, major degradation 
products identified and the antibacterial activity of degraded solution was 
measured.  
 
In this study, we also compared the PK and PD of traditional dosing 
(50mg/kg iv every 8 hour) versus CI of cefepime (100mg/kg/24hour), 
using standard two-stage PK modeling with ADAPT II software. The PD 
outcomes evaluated included sputum bacterial density, sputum 
interleukin-8 (IL-8) concentration and improvement in forced expiratory 
volume within 1 second  (FEV1).  
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In-vitro experiments revealed that cefepime stability at 24 hours following 
CI was 94.3±1.0%. The mean infusion bag temperature was 22.6±°1.5°C. 
Cefepime is stable for 15 days in a refrigerator and 10 hours at 37°C. The 
degradation includes cleavage of the R2 side chain and opening of the β-
lactam ring. Antibacterial activity appeared to correlate with intact 
cefepime remaining in solution (r2>0.74, p<0.001). The Arrhenius plot 
showed that the average temperature in the bag should not exceed 29.1°C 
in order to maintain 90% stability at 24 hours. 
 
The PK analysis showed that a two-compartment model best describes 
cefepime observed serum concentration. The two-compartment PK 
parameters were calculated with MAP-Bayesian algorithm and were 
found to be total clearance of 2.5mL/min/kg, distribution clearance of 
1.9mL/min/kg, distribution half-life of 0.53 hours, and elimination half-
life of 2.8 hours. The sample size in this study was too small to be able to 
make any significant distinction between PD outcomes in the patients 
receiving CI versus those receiving intermittent dosing. It was possible to 
observe a trend, being that patients with T>MIC 100% of the time had a 
greater decline in bacterial density, and a higher decline in the 
inflammatory marker IL-8. 
 
These results demonstrated that the stability of cefepime supports CI. A 
cold pack is necessary if the average temperature in the drug solution 
exceeds 29°C. Solutions of cefepime should be stored in a refrigerator if 
not used right away, and in a freezer if not used within 5 days. The PD 
results showed an indication of better clinical outcome with CI 
administration, however more patients are needed to show statistical 
significance. 
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1.2  Introduction 
1.2.1  Pathogenesis of cystic fibrosis 
 
Historical Perspective 
The first genetic step in understanding CF was made in 1946, when the 
inheritance of the disease was mapped. The study showed that it was a 
recessive condition caused by a mutation on one single gene coding for a 
protein (3). Another important historic landmark was made in 1953 when 
it was discovered that children with CF lost an excessive amount of salt in 
their sweat when compared with normal children (3). This discovery 
resulted in a cornerstone in diagnosis of CF, to measure chloride content 
in perspiration. The next major advance in basic research was made in the 
beginning of 1980s, when biochemical investigation revealed that sweat 
glands failed to absorb salt from the lumen of the glands, thus making the 
sweat salty.  At the same time a similar study of epithelial tissue in the 
airways showed no chloride movement and increased sodium uptake. 
These discoveries lead to the conclusion that some chloride channels in 
epithelial tissue were malfunctioning (3). The complete identification of 
the CF gene was achieved in 1989 (6), and with this knowledge it is 
possible to give a good description of the disease.      
 
An interesting phenomenon is why such a deadly disease just did not 
disappear with the early death of the patients. One possible explanation 
that has been suggested is that there is a heterozygote advantage to the 
carriers of one mutant CFTR gene. In particular, carriers of the mutant 
CFTR gene may be more resistant to secretory diarrhea diseases (4). One 
experiment with a CF-mouse model showed that CF-mice did not secrete 
fluid in response to cholera toxin. This supports the hypothesis that CF-
carriers have an advantage in surviving cholera (7). 
 
Genetics and functions of CFTR 
The CF gene is located on chromosome 7, and it codes for a protein that 
functions as a chloride channel called: Cystic Fibrosis Transmembrane 
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conductance Regulator (CFTR) (8). CFTR is an apical epithelial 
transmembrane protein, which is a member of the ATP Binding Cassette 
family. It utilizes energy from hydrolysis of ATP to undergo a 
conformational change that opens the channel to anions. These ion-
channels have best selectivity of bromide, then chloride and least for 
iodide (1, 4). CFTR is regulated by phosphorylation of protein kinase A, 
and is mediated by cAMP (4). In the case of a malfunctioning CFTR the 
chloride conductance is reduced, resulting in failure of reabsorption of 
chloride in the sweat ducts, and failure of chloride secretion in lung tissue 
(4). In the sweat glands CFTR is the only available anion conductance 
pathway, so with lost function the lumen becomes highly electronegative 
and transport (absorption) ceases. The result is a high luminal salt 
concentration (1).  
 
Another important electrophysiologic malfunction of the epithelial cells in 
CF lung tissue is the increased absorption of sodium ions. This cannot be 
explained by failure of the CFTR mediate chloride secretion alone, but 
through another function of CFTR: the regulation of other proteins. The 
most documented other function is its negative regulation on the 
amiloride-sensitive epithelial sodium channel (EnaC) (9). CFTR lowers 
EnaCs probability to be in an open conformation (9). The absence of 
functional CFTR disrupts the negative control resulting in markedly 
increased sodium conductance in CF human airways (10). 
 
Recently as many as 1000 different mutations in the CF gene have been 
discovered (http://www.genet.sickkids.on.ca/cftr/). The most common 
mutation is ∆F508, and this mutation results in deletion of phenylalanine 
at 508th amino acid at CFTR. Among white British CF patients, 70% are 
homozygote for this mutation (8).  
 
The diagnosis of cystic fibrosis 
The hallmark of CF is an elevated chloride content in sweat. Only 0.1% of 
patients with typical lung and/or involvement of other organs have normal 
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sweat chloride concentration (11). A sweat chloride concentration over 60 
mEq/L is diagnostic of CF (4). The classical diagnostic triad also 
includes chronic sino-pulmonary disease and pancreatic insufficiency. (4). 
Some helpful criteria in the diagnosis are azoospermia in males and 
mucoid Pseudomonas aeruginosa in sputum culture (4). 
 
There is also a possibility to get newborns screened for CF, so that 
treatment can start earlier (8).  One limitation to this approach is the large 
number of mutations that are currently not routinely screened, due to the 
relatively low frequency of occurrence. 
 
CF Lung Disease 
Lung disease is of particular importance since it causes 90% of the 
mortality and is the primary reason for hospitalization. The mortality is 
caused by chronic bronchitis that develops into bronchiectasis and finally 
respiratory failure (5). The pathogenesis of the lung disease develops from 
almost normal lungs at birth into chronic infection and inflammation (4).   
 
There is still no complete understanding of how defective CFTR gives 
rise to the lung disease, but some possible mechanisms do exist. The 
mucus that covers the airway surface is abnormally thick and impairs the 
ciliary clearance of the airway. This may allow bacterial infections to 
become established  (4). In response to the infection, there is production 
of proinflammatory cytokines including interleukin-6, tumor necrosis 
factor-α, and IL-8 by alveolar macrophages and bronchial epithelial cells. 
IL-8 in particular is a potent neutrophil chemoattractant. (8). Due to the 
persistence of the lung infection there is an exaggerated inflammatory 
response within the airways of CF patients resulting in the release of 
oxidants and enzymes (i.e. neutrophil elastase), which cause structural 
damage to the lung tissue (3). Dying neutrophils release 
deoxyribonucleotide acid (DNA), which increases the viscosity of the 
sputum and leads to airway obstruction. The infection and inflammation 
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become self-sustaining, and ultimately result in bronchiectasis and 
respiratory failure  (4).  
 
Lung infections in children with CF typically are caused by 
Staphylococcus aureus or H. influenza. In contrast, in late childhood and 
in adults, P aeruginosa is the most common pathogen isolated from the 
airways. A problem in treatment is the growing resistance of P. 
aeruginosa to many of the existing antibiotics. In particular, P. 
aeruginosa has recently been shown to grow within biofilms that provide 
a barrier to antibiotics and impairs acquired host defense mechanisms (5).  
 
Treatment of Lung Disease 
The treatment of the lungs includes reducing the airway obstruction and 
managing the infection (5). To reduce airway obstruction, chest 
physiotherapy combined with postural drainage, will loosen and facilitate 
mobilization of mucus and improve lung clearance, especially over long 
periods (5, 12). Less time-consuming and newer techniques include 
airway oscillation (Flutter device) and high-frequency chest oscillation 
(ThAIRapy Vest). 
 
A great deal of CF-patients will experience improved pulmonary function 
with the use of bronchodilator therapy, which should be considered when 
it increases the FEV1 with 10% (13). Bronchodilators also facilitate 
mucus clearance (4). Additionally, reducing the viscoelasticity of sputum 
can assist in relieving airway obstruction. A purified recombinant human 
deoxyribonuclease I (rhDNase I) has demonstrated to significantly reduce 
sputum viscosity (14) and improve the FEV1 (13).  
 
Treating the infections with antibiotics has contributed to increased 
survival in CF-patients. Antibiotics are used both to treat exacerbations of 
pulmonary infections, but also as chronic maintenance therapy, either as 
oral or inhaled administration to increase the time between the 
exacerbations (5).  
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Appropriate treatment of exacerbations consists of parenteral 
administrations of 2 antibiotics for 14-21 days, along with intensified 
airway clearance and bronchodilator administration (13). The most 
common regimen is the combination of aminoglycoside and β-lactam 
antibiotics; however, the choice of antibiotics should always be based on 
identification and susceptibility of the bacteria isolated from sputum (13). 
To avoid resistance in bacteria and achieve synergistic effect, drug-
combinations should have different mechanisms of action.  The use of 
antibiotics in the treatment of acute pulmonary exacerbations has been 
shown to result in a significant decline in density of P. aeruginosa in 
sputum. In addition, the decline in bacterial density correlates with 
improvement in FEV1 (15). 
 
Since a significant contribution of the lung tissue destruction is due to 
inflammation, a number of anti-inflammatory compounds are currently 
under investigation (4).  While studies have demonstrated significant 
benefits with long-term administration of corticosteroids, the trials were 
discontinued due to intolerable adverse effects including growth 
retardation, glucose intolerance, and cataracts. High dose ibuprofen 
therapy has also shown to reduce pulmonary deterioration; however, the 
numbers of patients studied to date are too few to provide any estimation 
of the relative safety of this treatment. Macrolides also exhibit potent anti-
inflammatory effects and have resulted in increased survival in patients 
with diffuse panbronchiolitis, an illness similar to CF. There are currently 
several large controlled studies investigating the clinical effects of 
macrolides in CF-patients (8). Since the deterioration in pulmonary 
function begins in childhood, early therapy is desirable (5). 
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1.2.2 Rationale for continuous infusion of cefepime and other β-
lactam antibiotics 
 
The time that drug concentrations exceed the minimal inhibitory 
concentration (T>MIC) is the best PK/PD parameter to determine the 
efficacy of cefepime and other β-lactam antibiotics (16). This is explained 
by the fact that cefepime and other β-lactam antibiotics exhibit time 
dependent bacterial killing within the therapeutic dosing range, meaning 
higher serum concentration do not increase the bacterial killing. It is also 
important to keep the serum level well above the MIC to minimize the 
risk of developing resistance (17). In addition cefepime exhibits only a 
short post-antibacterial effect (PAE), against susceptible organisms. This 
is especially important in CF patients who exhibit enhanced clearance of 
many antibiotics (3).  
 
CI is an efficient method of administration that will maximize T>MIC 
throughout the dosing interval, keeping the bacterial growth suppressed at 
all times. Cefepime also has a relatively short biological half-life, making 
it preferred to have a frequent dosing interval. Results from a few clinical 
trials conducted in critically ill patients and patients with CF suggest that 
CI may be the optimal method administration for β-lactams, since CI 
shows similar efficacy at a reduced dose (17-19). A lower incidence of 
adverse effects has been reported with CI presumably because many side 
effects occur at peak levels that are avoided with CI. 
 
Other benefits of CI administration are that it minimizes the cost of 
treatment by using less drug while achieving the same effect compared 
with standard dosing (20). In addition, CI with a portable infusion pump 
makes it possible for patients to be more mobile and have the opportunity 
of being treated at home. This significantly improves quality of life for 
patients with CF. 
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While the above attributes suggest many advantages of CI of β-lactams, 
there are a few potential drawbacks to this method of administration. 
Since the infusions are continuous, only compounds that have 
demonstrated compatibility can be infused through the same intravenous 
line. In addition, only β-lactams which are stable at room temperature for 
greater than 24 hours can be administered by CI. Finally, some data show 
that resistance can emerge more rapidly after CI than bolus dosing (17); 
however, since combination therapy is routinely prescribed for patients 
with CF, this is unlikely to be clinically significant.  
 
 
1.2.3 Cefepime: Activity, dosing in CF/normal patients  
 
Cefepime is a broad-spectrum semi-synthetic 4th generation cephalosporin 
for parenteral administration (21). It was developed by modifying the 
third generation cephalosporin-class (22). The classification into 4th 
generation is based on its broader spectrum of activity and its decreased 
susceptibility to certain β-lactamases (23). Cefepime is a zwitterion (see 
figure 1) with a net neutral charge that allows it to penetrate the outer 
membrane of Gram-negative bacteria faster than the third generation 
cephalosporins  (22). 
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Figure 1: Cefepime with the chemical name 1- [[6R,7R)-7- [2-(2-amino-
4-thiazolyl)-glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo [4.2.0] 
oct-2-en-3-yl] methyl]-1-1 methylpyrrolidinium chloride ,72-(Z)-(O-
metyloxime), monohydrochloride, monohydrate. The molecular formula is 
C19H25ClN6O5S2•HCl•H20 
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Cefepime is a bactericidal agent that acts by blocking bacterial cell-wall 
synthesis (21). It exhibits activity against both Gram positive and Gram-
negative bacteria. Its activity against Gram-negative species separates it 
from the third generation cephalosporins. Cefepime has a low affinity for 
chromosomally encoded β-lactamases, and is highly resistance to 
hydrolysis by most β-lactamases  (21). It has activity against the most 
common bacteria in CF patients, which include Pseudomonas aeruginosa, 
Heamophilus influenzae and Staphylococcus aureus, but not against the 
rare infection with Stenotrophomonas maltophilia (21).  
 
Distribution 
After parenteral administration cefepime distributes widely into 
extracellular fluid within tissues including bronchial mucosa and 
sputum(23). The average steady state volume of distribution is 
approximately 0.26 L/kg in healthy volunteers. Cefepime exhibits 
concentration independent serum protein binding of about 20% (21).  
 
Metabolism and Excretion 
Cefepime is principally eliminated unchanged via renal excretion (see 
figure 2) with a half-life of two hours, and total body clearance of 120 
mL/min in healthy volunteers  (21). Cystic fibrosis patients demonstrate 
increased drug clearance of a number of compounds when compared with 
age-matched controls. CF patients have 19% higher clearance of cefepime 
than normal patients, which is caused by increased renal and non-renal 
clearance (24). The increased clearance and the fact that P. aeruginosa is 
a less susceptible organism necessitates the use of higher doses for 
adequate treatment. The maximum recommended dose of cefepime, 50 
mg/kg (max 2g per dose) every 8 hours, has been utilized in several 
studies involving cystic fibrosis patients (24, 25). 
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Figure 2: Disposition of cefepime in humans. 85% is excreted unchanged 
in urine. 
 
Patients exhibiting renal insufficiency require dosage adjustments, and 
creatinine clearance can serve as a basis for dosage determination (21). 
The PK of cefepime does not appear to be affected by hepatic impairment 
(23). Cefepime exhibits linear PK over the dosing range of 250mg to 2g 
per day (23).  
 
The adverse effects reported are similar to those with other parenteral 
cephalosporins, and cefepime is generally well tolerated (23). Headache, 
rash, diarrhea, nausea and vomiting have been reported for 2% of the 
patients, while neutropenia is present in less than 1% of patients (23).  
Approximately 3% of the patients discontinue drug therapy due to adverse 
effects (23). 
 
 
1.2.4 The relevance of testing cefepime stability 
 
In order to support CI administration of a drug it is necessary to establish 
that the desirable drug in solution is stable throughout the administration 
period.  Previous studies indicate that cefepime is stable for 24 hours at 
room temperature (26).  However there is conflicting information on 
Cefepime 
N-metylpyrrolidine(NMP) <1% 
NMP-N-oxide 6.8% 
Cefepime epimer 2.5% 
Unchanged cefepime 85% 
Metabolized 
Rapid 
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whether cefepime is stable for 24 hours at body temperature (27). The 
information on temperature and stability of cefepime when administered 
using portable infusion pumps when worn for a 24-hour period is 
currently unknown.  
 
There are at least two major classes of portable pumps in clinical use 
today, the disposable elastomeric and the motorized peristaltic pumps. 
The advantage of the elastomeric pumps is that they are simple to operate 
and are economical; however, they appear to be more influenced by body 
temperature since they are worn under the clothing. In contrast, the 
peristaltic pumps allow more precise control of flow rate and are less 
influenced by body temperature since they are typically contained within 
an external pouch.  
 
Therefore, we chose to study the temperature variation and stability of 
cefepime using a motorized portable infusion device. The purpose of this 
study is to determine if cefepime is stable enough to be administrated by 
CI using a motorized portable infusion pump, and to define optimal 
conditions for storage prior to administration. 
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2. STABILITY, DRUG-RESERVOIR TEMPERATURE AND 
ANTIBACTERIAL ACTIVITY OF CEFEPIME DURING 
CONTINUOUS INFUSION ADMINISTRATION  
 
 
2.1 Scope and intent 
 
The purpose of this study is to determine if the stability and antibacterial 
activity of cefepime supports CI administration. 
The specific aims of this study are: 
- Determine the stability of cefepime during simulated CI 
administration with (Microject 30, Sorensen Medical) portable 
infusion pump for 24-36 hours. 
- Determine the average temperature with TempTrace in the drug 
reservoir while using portable pump system. 
- Identify potential cefepime degradation products with mass 
spectrometry, and determine their relative antibacterial activity. 
- Determine optimal storage conditions for drug-reservoir before 
use. 
- Determine the stability at fixed temperatures; 5°C  (refrigerator), 
21°C (room temperature) at 37°C (body temperature), and at 55°C 
to be able to make an Arrhenius plot that will provide more 
information on how the stability changes according to 
temperature. 
 
The results of this study will provide support for clinical trials evaluating 
CI cefepime administration in the treatment of CF pulmonary 
exacerbations and nosocomial pneumonia. In addition, this data will 
provide information useful for the optimal storage and analysis of 
cefepime.
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2.2 Methods 
2.2.1 HPLC assay 
 
The HPLC assay was a modification of a previous published cefepime 
assay (28). Chromatography was preformed isocratically on an analytical 
reversed-phase C-18 column with a C-18 precolumn. The mobile phase 
consisted of 8% v/v acetonitrile in 20mM ammonium acetate, adjusted to 
pH 4.9 with glacial acetic acid, all chemicals  HPLC grade quality. The 
mobile phase was filtrated through a 47mm 0.22µm nylon membrane 
filter before use. Flow-rate was set at 1.0 mL/min. Cefepime was detected 
at its absorption UV-peak at 260nm (29). The standard curve was made 
with known concentrations of cefepime in HPLC-grade water, measured 
in triplicate.  
 
The procedure for the samples was simple, utilizing only one dilution 
1:100 with HPLC-water and filtration through a 0.2µm 4mm nylon 
membrane filter before injection. 
 
 
2.2.2 Stability and drug-reservoir temperature during simulated 
continuous infusion 
 
To best mimic the actual patient conditions during CI and estimate the 
stability and temperature in the infusion bag as best as possible, CI of 
cefepime was simulated by using a portable motorized infusion pump 
(Microject 30, Sorensen Medical), that provides continuous low flow 
rates. This pump and the drug solution reservoir are contained in two 
different and separated bags on the same convenient light bag system. 
This bag is worn like a belt, and is easy for the patients to carry around. 
The bag also protects the drug reservoir against light exposure. From the 
pump, the drug solution is pumped through a cassette and into the vein. In 
this study, the drug was pumped into a waste bag (same type as drug 
reservoir), which was also worn on the same belt. See figure 3. 
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Figure 3: Schematic drawing of the infusion during CI for a real patient 
(a) and for the stability study(b). In this study all the components were 
worn different pouches on the same belt. 
 
The dose chosen for this study was derived from prior work evaluating CI 
ceftazidime (30), which exhibits  similar pharmacokinetics as cefepime 
(24, 25, 31). Cefepime is normally dosed according to the patients 
weight, 100mg/kg/24hour (max 6g/24hour).  One previous study 
demonstrated that cefepime follows first order degradation (26), we 
sought to confirm that different concentrations do not affect the stability. 
This was done by testing cefepime stability in the concentrations ranging 
from 2g/250mL to 6g/250mL. Cefepime solutions were made with sterile 
Maxipime, containing arginine (as a buffer) in a concentration of 725-
mg/g cefepime to control the pH.  
 
Cefepime was admixed volumetrically to the accurate concentration with 
sterile D5W. To mimic the patient situation three individuals wore the 
pump and bag containing cefepime for 24-36 hours. Seven 2mL samples 
were extracted from the administration bag during the 24-36 hours. These 
samples were frozen at -70ºC until assayed. This method attempts to 
provide useful information on how the temperature varies in the drug 
reservoir and its impact on cefepime stability during a simulated CI. In 
addition these simulations also determines temperature variations among 
various individuals, and whether concentration will have impact on the 
cefepime stability. The measured stability after 24 hours during simulated 
CI will be used to determine clinical stability (> 90% cefepime 
remaining). 
 
Drug 
reservoir with 
cefepime 
Pump 
Waste bag (for 
the study)b  
Blood (for 
patients)a 
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Temperature changes in the drug reservoir were measured every 30 
minutes using an electronic temperature detector (TempTrace) that was 
placed adjacent to the drug reservoir. The detector was then connected to 
a computer with software for TempTrace, which printed out the 
temperatures..  
 
 
2.2.3 Stability during various storage conditions 
 
In order to simulate an actual home-case treatment situation, the drug 
reservoirs were stored for one or two weeks in a freezer (-15.5°C) as well 
as in a refrigerator (3.8°C) (for a total of four bags) before CI 
administration as described previously. This provides information on the 
stability of cefepime for home treatment, where the patients receive drug 
supplies for either one or two weeks at a time. It also provides data on 
how the patients need to store the cefepime bags prior to use.  
 
Two additional experiments were performed to give additional 
information on degradation of cefepime under various conditions. The 
first experiment used the Arrhenius equations to predict the degradation 
rate at a certain temperature, given that the degradation rate for at least 
one other temperature is known and that the degradation is first order. 
This method is commonly used to predict the shelf life of drug products. 
The Arrhenius equation is comprised of: log k= log A  Ea/(2.303RT), 
where k is the degradation rate constant, Ea is the activation energy 
needed to start a reaction, A is the frequency factor assumed to be 
independent of temperature, R is the gas constant (8.314 J mol-1K-1) and T 
is the temperature in Kelvin (32).  
 
This equation provides information about the stability of cefepime when 
stored under temperatures ranging from 4° to 55ºC. These different 
degradation rates were calculated  by admixing eight infusion bags with 
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the same concentration (1g/50mL) of cefepime in D5W in EVA bags, and 
storing them at 4 different temperatures (4º, 21º, 37º and 55ºC). The 
respective degradation rates were calculated under these conditions. The 
two highest temperatures were maintained using a temperature-controlled 
water bath. For the remaining two samples the temperature was 
maintained by storing the bags in room temperature and in a refrigerator 
respectively. The duration for each experiment was dependent upon the 
temperature for which they were stored:  4ºC for 2 weeks, 21ºC for 1 
week, 37ºC for 2 days and 55ºC for 8 hours. The degradation rates were 
calculated from the first 25% degradation, where the degradation is first 
order. The complete degradation does not follow first order kinetics, as 
discussed later. Seven samples were obtained from each bag during each 
experiment. The samples were frozen at 70ºC until assayed by HPLC. 
The information from the different degradation constants at each 
temperature tested was used to generate an Arrhenius plot. This plot was 
also used to calculate at which temperature the stability would be 90%. 
This temperature gives the limit of what the average temperature in the 
bags must be kept below to keep the drug stable enough to support CI. 
 
The second experiment was performed to  completely investigate the rate 
of degradation of cefepime over the entire concentration range. In 
addition, potential differences  of cefepime stability in different bags were 
evaluated. Three EVA and two PVC bags with 1g/50mL cefepime were 
exposed to a 37°C water bath for a long enough period to degrade 
completely. Samples were taken twice a day for 6 days. Since the 
degradation rate is pH dependent, pH was measured for each sample.  
 
 
2.2.4 Determination of degradation products  
 
Putative cefepime degradation products were determined using a 
Micromass Quattro Ultima triple quadrupole tandem mass spectrometer 
(Micromass, Beverly, MA) running in positive ion mode. Briefly, drug 
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solutions determined to have differing degrees of parent drug degradation 
by HPLC were introduced into the mass spectrometer using a syringe 
pump (Harvard Apparatus, Holliston, MA) running at a continuous rate. 
Total ion signatures for each solution were obtained by averaging scans 
collected over a 2-minute interval.  Mass ion signatures from a fresh 
solution, 5%, 20%, 45% and a completely degraded cefepime solution, 
were used to identify the degradation products. By following the 
appearance of new mass ions in the degraded samples and comparing the 
mass changes in the samples with previous studies done looking at the 
degradation of ceftazidime (a compound related to cefepime, see figure 4) 
(33, 34), the major breakdown products were identified.  
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Figure 4: Chemical structures of cefepime and ceftazidime 
 
 
2.2.5  Correlation between cefepime stability and in-vitro 
antibacterial activity 
 
Both MICs and minimal bactericidal concentration (MBCs) were 
determined for a freshly prepared solution, and five solutions of cefepime 
containing 87% to 12% active cefepime, and varying concentrations of 
cefepime degradation products. All tests were performed in quadruplicate. 
The measured MICs were plotted against cefepime concentration 
remaining to determine if a relationship exists between observed MIC and 
percent cefepime remaining after degradation. This enables determination 
of whether the degradation products have any antibacterial effects. 
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MICs were determined by using macrodilution with a fixed inoculum of 
1x 106 colony forming units per gram (CFU/g) of a reference strain 
ATCC 27853 of Pseudomonas aeruginosa and Mueller-Hinton broth 
adjusted with calcium and magnesium according to the National 
Committee for Clinical Laboratory Standards (NCCLS). The standard 
inoculum was prepared by diluting the reference strain to the same 
turbidity as a 0.5 McFarland solution to achieve the same density, which 
ideally will give a solution of 1x106CFU/mL. The dilutions of antibiotic 
were prepared volumetrically in broth, which after 1:1 dilution with the 
inoculum gave dilutions of 5x 105 CFU/mL of the reference strain. 
Diluting the inoculum with a factor of 104 and counting colonies on agar 
after 24 hours incubation gave the exact density.  
 
MBCs were defined as the dilution that killed over 99.9% of the bacteria. 
That was found by incubating the MIC-dilution and higher concentrations 
on 0.5% blood agar in 37°C for 24 hours determined. The colonies were 
counted and the lowest dilution that had killed 99.9% of the initial density 
was the MBC. A summary of test solutions and the MICs tested are 
shown in table 1. 
 
 
Table 1: The second column shows the percent of intact cefepime left in 
the solutions tested and the third column shows the dilutions of 
cefepime(µg/mL) that MIC were tested.. 
 
Solution Percent active MIC samples 
1 100% 0.5,1,2,4,6,8,10,12 
2 87% 0.5,1,2,4,6,8,10,12 
3 74% 0.5,1,2,4,6,8,10,12 
4 45% 0.5,1,2,4,6,8,10,12 
5 30% 2,4,6,8,12,16 
6 12% 4,8,12,16,20,24,28,32,64 
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2.2.6  Statistics 
 
Statistical analysis was performed using Graphpad Prism version 3.03 
(Graphpad Software Inc. San Diego, CA). The Students t-test was used 
to compare the measured stability versus the 90% stability limit, and to 
compare MBCs with MICs. 
 
 
2.3  Results 
2.3.1 HPLC assay 
 
Assay validation 
The Standard curve was linear from 25-250µg/mL, with a correlation 
coefficient (CV) >0.999.  The intra-day and intra-day coefficients of 
variation were all under 3.48%. More assay information in the appendix. 
 
 
2.3.2   Stability of cefepime and drug-reservoir temperatures during 
simulated continuous infusion  
 
The stability of cefepime after 24 hours CI for 8 replicates of 6g/250mL 
was 94.2±1.1%. Four of the replicates were fresh solutions prepared for 
CI, and the other four replicates were taken from the experiments 
evaluating various storage conditions (stability from CI only was 
calculated by stability post infusion divided by stability after storage).  
Stability for the 2g/250mL and 4g/250mL were 95.0% and 92.4% 
respectively. When cefepime stability was evaluated after 30 hours the 
percent intact drug was 92.2±3.5%. Cefepime solutions administrated 
over 24 hours were significantly above the stability limit of 90% 
(p<0.0001).  
 
The temperature in the drug reservoirs showed some variation during the 
24 hours. Figure 5 displays the average temperature with standard 
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deviation of all the temperature measured during the simulated CI in all 
ten bags. The average temperature was 22.6±1.5°C, (mean maximum and 
minimum temperatures 28.0±1.9°C, and 16.6±2.5°C respectively). All of 
the experiments were started in the morning and ended the next morning. 
87.5 % of all the average temperatures were between 20 to 25°C. 
  
Figure 5: Variability in temperature throughout 24-hour CI period 
(n=10) 
 
 
2.3.3 Stability of cefepime during various storage conditions 
 
The results from all storage experiments are summarized in figure 6, 
which has four paired columns, representing storage condition. Shadowed 
columns depict the stability of cefepime after only storage conditions, 
while unshaded columns represent the stability after the same drug-
reservoir has been worn as a simulated CI for 24 hours. The cefepime-
solution was stable enough after storage and simulated CI in all 
experiments with the exception of the one following two weeks storage in 
a refrigerator. Cefepime stored at 4°C in refrigerator for two weeks was 
found to have 90.5% parent drug, and after the same solution was worn as 
simulated CI for 24 CI the parent drug concentration was declined till 
85.3 %. 
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Figure 6: Stability of cefepime solution after four different storage 
conditions. Each paired column represents one storage condition. The left 
column of the two-paired columns represents the stability after the 
respective storage. The right of the two paired columns represents the 
stability of the solution after that the same drug-reservoir after storage 
has been used as a 24 hour simulated CI. The solid line represents the 
stability limit of 90%.  
 
The complete degradation of cefepime in D5W in 37°C showed a 
disparity from the previously proven first order kinetics. The observed 
degradation and a theoretical first-order kinetic breakdown are compared 
in figure 7, which also show the pH in the solution while cefepime is 
degrading. 
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Figure 7. Degradation of cefepime at 37°C.  The thick line indicates how 
cefepime would degrade if it follows perfect first order kinetics at 37°C. 
The stippled line (declining) shows the degradation observed in the 
experiment. Both the stability curves have values on the left Y-axis. The 
dotted line  (increasing) shows the measured pH during the cefepime 
degradation, with respective values on the right Y-axis. 
 
This is consistent with previously described information suggesting that 
cefepime degradation is pH-dependent (26), and is most stable in the pH 
range of 4  6. As figure 7 shows the degradation rate increases as the pH 
reaches a level over 6. The pH increase is due to accumulation of alkaline 
degradation products that increases the pH. This resulted in an increased 
degradation of cefepime, and a deviation from first order kinetics.  
 
The complete degradation of cefepime in D5W from the commercial 
product Maxipime follows first order kinetics in the first 25% of the 
degradation (r2>0.97), while the rest of the degradation does not follow 
first order kinetics and is best described as an empirical breakdown. 
Cefepime degradation was also associated with colorimetric changes. A 
fresh solution of 24 mg/mL is clear, but after 10% degradation it becomes 
pale yellow, after 20% degradation it is yellow, after 30% and more it 
turns orange, and complete degradation has orange/brown color. Thus the 
degradation products probably have a brownish color. Cefepime solution 
showed less than 0.5% difference (p>0.81) in degradation between EVA 
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and PVC containers in the first 30.5 hours (or 70% degraded cefepime) in 
37°C. After 48 hours cefepime appeared to degrade more rapidly in EVA 
than PVC containers, the difference in mean values was 8.0% (p= 0.038). 
 
The stability results from all experiments at 4 different temperatures were 
used to calculate the Arrhenius plot seen in table 2 and figure 8. 
 
 
Table 2: This table describes the 8 bags used for determining the 
Arrhenius plot. First column gives the temperature in Celsius, the second 
gives temperature in Kelvin and the third gives the reciprocal of 
temperature in Kelvin. The fourth column shows the measured 
degradation constant (k), and the fifth gives the logarithm of k. The last 
column gives the average of the two degradation constants. 
 
 
Temp(C) Temp(K) 1/T k log k Average 
55 328 0.003049 0.053200 -1.2741 -1.272 
55 328 0.003049 0.053720 -1.2699   
37 310 0.003226 0.009897 -2.0045 -1.994 
37 310 0.003226 0.010380 -1.9838   
20.8 293.8 0.003404 0.001879 -2.7261 -2.724 
20.8 293.8 0.003404 0.001896 -2.7222   
1.4 274.4 0.003644 0.000186 -3.7317 -3.748 
1.4 274.4 0.003644 0.000172 -3.7652  
 
 
Plotting the reprocidal of temperature against the average logarithmic of 
the degradation rate gives the Arrhenius plot seen in figure 8. 
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Figure 8: The Arrhenius plot of the degradation rate (k) of cefepime for 
four temperatures ranging from 1°C -55°C. Temperatures on the x-axes 
are multiplied with 1000. The four points made a straight line (r>0.99), 
with slope of  4.16x103and intercept of 11.4. The activation energy was 
calculated to be 81.4KJmol-1K-1. 
 
To calculate the temperature that will give 90% stability of cefepime in 24 
hours the equation for a first order degradation, C=C0e-kt, was used. 
100%=90%x e-k x 24h was solved to give k=0.00439. The temperature that 
will give k=0.00439 was then solved mathematically by the equation t= 
1/((11.4-log 0.00439)/4157))-273°C, since the plot is a straight line 
(Y=ax+b) and a is the slope and b is the intercept, and Y=log k. This 
equation gave the temperature that will give 90% stability in 24 hours as 
29.1°C.  
 
The Arrhenius plot was also used to predict the stability of cefepime 
during storage in refrigerator and freezer. This was done by first finding 
the log k for the wanted temperature by using the Arrhenius slope, log k = 
slope x 1/T + b, and then using the equation describing degradation of a 
first order kinetics: C=100% x e-kt. The stability in refrigerator was 
calculated to be 95.8% after 1 week and 91.8% after 2 weeks. In the 
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freezer the stability after one and two weeks were 99.6% and 99.3% 
respectively.  
 
 
2.3.4 Determination of degradation products 
 
Mass spectrometry data indicated that degradation of cefepime includes 
cleavage of N-methylpyrrolidine  (R2-side chain, see figure 4) and 
opening of the cephem (β-lactam ring) as shown in figure 9.  
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Figure 9: Shows putative main breakdown pathway of cefepime. The main 
degradation occurs when the β-lactam ring opens, and R2 side chain is 
cleaved off. 
 
 
It also indicates that the ring opening occurs before the cleavage of N-
methylpyrrolidine. This was observed  from the relative amount of 
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degradation products seen in the mass scans after different amounts of 
cefepime have degraded. There were no observed degradation products 
where ring opening had occurred without N-methylpyrrolidine cleaved 
first. Figure 10 highlights the change in mass scans when the solution is 
degrading.  
 
 
Figure 10: Changes in mass signature during degradation. On top is the 
mass signature of a freshly prepared cefepime solution, and on bottom is 
the mass signature of a degraded solution. The structures of putative 
degradation products are placed over their respective molecular weight 
(MW).  MW=175 is the buffer arginine. MW+1=86 is N-
methylpyrrolidine. 
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The mass scan of the fresh solution shows that even the fresh made 
solution is to some degree broken down, this can be explained since we 
were using commercial product that may have already been stored for 
some time. In addition, some degradation will occur during the freezing 
and thaw procedure. This experiment was done to map qualitative more 
than quantitative changes in cefepime and its degradation products.  
Cefepime (molecular weight (MW)=481) is clearly decreasing and the 
degradation products with MW= 158 and 86 (N-methylpyrrolidine) are 
increasing as a result of degradation of cefepime. Since we were primarily 
interested in major breakdown products, no fragmentation was performed. 
Structure 5, 2-[[2-amino-4-thiazolyl)((Z)-methoxyimino) acetyl] amino] 
acetoaldehyde, in figure 9 is a reactive amine structure and is likely 
broken down further in a rapid manner, since this structure was not 
detected at any other time of the degradation. Additional work is 
necessary to completely map the breakdown pathway of cefepime in 
water-based solutions. 
 
 
2.3.5 Correlation between cefepime stability and in-vitro 
antibacterial activity 
 
Cefepime exhibited excellent in-vitro activity against the reference strain 
of P. aeruginosa with the MICs of the freshly made solutions all 
measuring 4 µg/ml, which is below the NCCLS breakpoint for 
susceptibility. The MICs and MBCs were not significantly different from 
one another demonstrating the potent bactericidal activity provided by 
cefepime against P. aeruginosa (p<0.83). The measured MICs plotted 
against intact cefepime remaining in the degraded solutions are shown in 
figure 11.  
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Figure 11: Antibacterial activity during cefepime degradation. Measured 
MICs with standard deviation on the y-axes are plotted against remaining 
cefepime concentration in percent on the x-axes. The solid line represents 
a first order polynomial fit of the observed MICs, and the stippled 
represents a second order polynomial fit.  
 
The first order polynomial fitting indicates that the MICs increased 
linearly with decreasing amount of intact cefepime remaining (r2>0.73, 
p<0.0001). This data suggests that the antibacterial activity is proportional 
with intact cefepime concentration, and the degradation products exhibit 
no antibacterial activity.  The second-order polynomial (r2=0.90) indicates 
that it is not a direct proportional correlation between intact cefepime and 
antibacterial effect. 
 
 
2.4 Discussion 
2.4.1 Cefepime stability and drug-reservoir temperatures 
 
A number of prior studies have been conducted to evaluate the stability of 
cefepime under various conditions. The most complete study on cefepime 
stability evaluated the impact of pH, temperature, and buffers on cefepime 
degradation (26). This study demonstrated that cefepime is stable for two 
days at temperatures up to 30°C. Williamson et al showed that in a 
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peritoneal dialysis solution cefepime would be stable for two days at body 
temperature (37oC) (35). Similarly, the manufacturers product 
information states that the stability in D5W is up to 24 hours when 
temperatures are maintained between 20°C and 25°C (Cefepime product 
monograph Bristol-Myers Squibb Company, July 2000). These data 
indicate that cefepime should be stable when administered as a CI over 24 
hours. Our data support this conclusion demonstrating that the 
temperature in the drug reservoir remained below 29.1°C resulting in 
clinically insignificant drug loss over a 24-hour interval.  
 
In contrast, Viaene et al recently published an evaluation of cefepime 
stability and concluded that cefepime is not sufficiently stable to support 
CI administration using portable infusion pumps (27). The design of this 
study differs from this one in two ways: the temperature utilized in their 
experiment and the diluent used to admix the cefepime solution. In the 
study, Viaene et al. used portable elastomeric pump to evaluate the 24-
hour stability of cefepime when administered as a CI. Portable 
elastomeric pumps are utilized commonly in the outpatient setting due to 
their ease of use and are relatively inexpensive. However, these pumps are 
typically placed under the clothing in close proximity to the body. Thus 
the temperature of the drug solution within the reservoir approximates 
normal body temperature. In the study by Viaene et al. they chose a 
temperature of 25°C and 37°C to simulate the conditions expected in a 
patient receiving cefepime via a portable elastomeric device. In this study 
we utilized a motorized portable infusion pump that was placed in an 
external pouch (separate from the drug reservoir) worn around the waist. 
Therefore, the higher temperature could explain the greater degradation 
noted in their study (10% degradation over 13 hours for 37°C and 10% 
degradation over 20.5 hour at 25°C) when compared with (5.7% 
degradation over 24 hours) in our study. Another potential contributing 
factor is the difference in diluents used in admixing of the cefepime 
solution. In the study by Viaene et al. sterile water was used as a diluent 
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in order to reduce the tonicity of the solution placed in the pump 
reservoir. Since the reservoirs for the elastomeric pumps are typically 50 
or 100ml, it is necessary to prepare highly concentrated solutions of the 
drugs to be administered using these devices. In contrast, with the 
motorized portable infusion devices there are no restrictions on the 
volume of fluid used to deliver the medication. We are unaware of any 
comparative data on the stability of cefepime in sterile water versus D5W. 
This data demonstrates the importance of testing the stability of 
compounds utilizing conditions that mimic those likely encountered by a 
patient. 
 
As seen in figure 5 the temperature between the experiments show little 
variation. The figures also show that the temperature increased to room 
temperature after admixing the solutions, and decreased during nighttime 
before they again increased in the morning. This is consistent with the fact 
that it is the room temperature that controls the bag temperature. 
 
One limitation to this study is that stability was not tested at the extreme 
ambient temperature that might be expected during summertime. Since 
the drug reservoir is influenced by ambient temperature, the environment 
in which the patient will be receiving the drug should be taken into 
consideration before giving the CI. For patients who will be outside in 
temperatures exceeding 29°C for any length of time should place a cold 
pouch adjacent to the drug reservoir to ensure stability of the cefepime 
administered. 
 
 
2.4.2 Stability of cefepime during different storage conditions 
 
According to the results derived from the Arrhenius plot a fixed 
temperature of 29.1°C will give 90% stability after 24 hours. While the 
Arrhenius plot is more correctly used for storage at a fixed temperature 
than with varying temperatures, it gives an indication of stability when the 
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variation is relatively small as it was in this experiment. The similarity of 
the 24-hour stability measurements using different concentrations 
indicates that the concentration did not affect the stability, which is 
consistent with a first order process. 
 
The in vivo stability of cefepime is to a very small degree influenced by 
chemical degradation. While cefepime has a biological half-life of about 2 
hours (21), the chemical half-life was measured in body temperature to be 
about 64 hours. Practically the chemical stability does not need to be 
considered in vivo. 
 
 
2.4.3 Degradation products 
 
Degradation includes cleavage of the R2 side chain and opening of the β-
lactam ring.  This was the expected breakdown of cefepime since two 
related compounds ceftazidime and cefpirome have shown similar 
breakdown (33, 36).  
 
One concern of CI of ceftazidime is that it breaks down to form the 
known toxic compound pyridine (27), this is not a concern for cefepime 
since pyridine is the R2 side chain only of ceftazidime (see figure 4). 
Cefepime has N-methylpyrrolidine as a R2 side chain, and is not broken 
down to pyridine. The toxicological effects N-methylpyrrolidine or the 
other breakdown products are currently unknown. With the recent 
knowledge in mind the degradation do not produce any toxic metabolite. 
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2.4.4 Correlation between cefepime stability and in vitro 
antibacterial activity 
 
The antibacterial activity of the fresh cefepime solution was compared 
with degraded solutions to investigate if the degradation products exhibit 
antibacterial activity. If the degradation products exhibit antibacterial 
activity the MICs would not have increased proportionally with the intact 
cefepime concentration, and the MIC observed would be lower than 
expected. The second order polynomial provided an improved fit to the 
data when compared with the linear model, indicating that the relationship 
between intact cefepime and antibacterial activity is not proportional. 
However, as seen in table 1, the MICs are not continuous values and some 
concentration gaps are up to 50%, indicating that high variations are 
possible. Due to the imprecise measurements in the MICs, both fits could 
be possible interpretations of the data. Both models indicate that 
degradation products do not exhibit antibacterial activity, based on the 
fact that MIC is increasing during degradation. 
 
 
2.5 Conclusion 
 
CI has proven to be a more efficient method of administration than 
intermittent dosing for antibiotics for which the bactericidal activity best 
correlates with time antibiotic concentration exceed the MIC (e.g. β-
lactam antibiotics). Due to fewer administrations times and reduced 
overall dosage, CI also has pharmacoeconomic advantages over 
traditional intermittent dosing of β-lactams. This study has shown that 
both the stability and the antibacterial activity of cefepime solutions 
support the use of 24 hour CI using a motorized portable infusion pump. 
 
Our data demonstrates that cefepime in D5W is stable (>90% active) after 
24 hours using a motorized portable infusion pump.  Since the drug 
reservoir is worn in an external pouch, the temperature in the drug 
  2.5 CONCLUSION 
 42
reservoir more influenced by the room temperature than by the body 
temperature, a fact clearly indicated by the average bag temperature of 
22.6±1.5°C.  The use of motorized portable infusion pumps and the bag 
system may be more suitable for CI regimens with drugs that exhibit 
temperature dependent stability.  
 
Our data demonstrates that cefepime in D5W is stable (>90% active) and 
maintains antibacterial activity after 24 hours using a motorized portable 
infusion pump (p<0.0001). The Arrhenius equation indicated that the drug 
solution must be keep in a average temperature below 29.1°C to maintain 
stability during a 24-hour infusion.  
 
In the case of home treatment, the cefepime solutions must be stored in a 
refrigerator, since degradation of cefepime occurs rapidly at room 
temperature. If the supply is for more than five days, it must be kept in a 
freezer and allowed to thaw in a refrigerator one day before use. This is 
based on the average degradation of 5.8% when administered as a CI over 
24 hours, and a 3% degradation over five days under refrigerator (4°C) 
conditions. 
 
The buffer added in the commercial product Maxipime keeps the pH in 
the drug solution within the pH-range where cefepime is most stable 
within the clinical use. 
 
The antibacterial activity decreases with a decreasing amount of cefepime 
remaining in solution, indicating that the degradation products exhibit 
very little or no antibacterial activity. The similarities in the MICs and 
MBCs in this study confirm the potent bactericidal activity of cefepime 
against P. aeruginosa. 
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3. PHARMACODYNAMICS AND PHARMACOKINETICS OF 
CONTINUOUS INFUSION VERSUS INTERMITTET 
INFUSION OF CEFEPIME IN PATIENTS WITH CYSTIC 
FIBROSIS 
 
3.1 Scope and intent  
 
This is a prospective, randomized comparative study with the purpose of 
comparing the PK and PD of continuous versus intermittent infusion of 
cefepime in cystic fibrosis patients, administered during an acute 
pulmonary exacerbation. More specific aims of this study are to compare 
the antibacterial and anti-inflammatory activities of continuous versus 
intermittent infusion cefepime in CF patients, and to determine if a 
relationship exists between improvement in pulmonary function and 
changes in airway inflammation and/or bacterial burden in CF patients 
treated for acute pulmonary exacerbations.   
 
3.2 The clinical study design 
 
The Institutional Review Board (IRB) at the University of Southern 
California approved this study. The inclusion criteria were: 
• Age ≥ 18 years 
• Confirmed diagnosis of cystic fibrosis, with either a positive sweat 
chloride test or an abnormal genotype. 
• Being admitted for treatment of an acute pulmonary exacerbation. 
• Have had a qualitative sputum culture within 6 months before the 
current admission for a pulmonary exacerbation. The predominant 
P. aeruginosa morphotype previously isolated was susceptible to 
cefepime or ceftazidime and tobramycin. 
• Patients must be capable of producing sputum samples on days 1, 
14 and after 1 month. 
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• FEV1 20-70% of predicted for age and height. 
• Have provided written informed consent. 
Following criteria excluded the patient form participating in this study: 
• History of hypersensitivity reaction to any cephalosporin, 
penicillin, carbapenem or aminoglycoside. 
• Renal insufficiency (predicted creatinine clearance 
<60mL/min/1.73m2), or hepatic dysfunction (ALT or AST > 3 
times the upper limit of normal; bilirubin> 1,5mg/dL. 
• A positive sputum culture for Burkholderia cepacia. 
• Pregnancy or nursing. 
 
The patients enrolled in the study was randomized to receive cefepime as: 
- A continuous infusion with the rate 100mg/kg/24hours (maximum 
6g/day) in dextrose 5% in water, with a loading dose of 15mg/kg 
(maximum 1g). Or 
- Intermittent infusion of 50mg/kg IV every 8 hours (maximum 6g/day). 
Each dose was infused over 30 min. 
 
The combination of an antipseudomonal β-lactam and an aminoglycoside 
are routinely prescribed for treatment of acute pulmonary exacerbations in 
patients with CF. In this trial intermittent or CI cefepime was 
administrated in combination with intravenous (IV) tobramycin 5mg/kg 
every 12 hour. Tobramycin dosage was adjusted to achieve peak 
concentration between 10-15 µg/mL and trough concentration less than 
1µg/mL. Since tobramycin and cefepime are incompatible (37) a double 
lumen central venous access device (PICC line) was utilized in patients 
receiving CI. 
 
The predicted serum concentration time profiles of CI and intermittent 
cefepime administration are illustrated in figure 12. With an intermittent 
regimen, cefepime serum concentrations drop below an MIC of 8 µg/mL, 
which represents the NCCLS breakpoint for susceptibility. 
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Figure 12: This figure illustrates a comparison of the concentration-time 
curve of CI 6g/24 hours with intermittent 2g every 8 hours. The MIC of 
8µg/mL represents the NCCLS breakpoint for susceptibility to cefepime. 
The values are calculated using the simulation module in ADAPTII PK 
program, with mean parameter values derived from prior studies in CF 
patients receiving intermittent administration of cefepime (24). 
 
The outcomes assessed in this study were: 
• Antibacterial effect, which was assessed by quantifying sputum 
bacterial densities.  
• Anti-inflammatory effect, which was assessed by comparing IL-8 
concentrations in urine and sputum. IL-8 is a proinflammatory 
cytokine that is secreted by different cells such as monocytes, 
neutrophils, endothelial cells, fibroblast after activation, and by 
mitogen-stimulated T lymphocytes. IL-8 is a potent neutrophil 
chemoattractant. 
• Pulmonary function was assessed using spirometry obtained prior 
to initiation, at the completion of therapy (14 days), and at 1-
month follow up. 
 
To ensure safety during this study, the patients received routine 
monitoring of renal function by measurement of serum creatinine and 
hepatic function by measurement of AST, ALT, bilirubin and alkaline 
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phosphatase every fourth day during therapy.  Patients were questioned 
about adverse events on a daily basis and any patient who developed a 
rash or other serious adverse effects attributed to cefepime were 
discontinued from the study.  
 
 
3.3 Materials and methods 
3.3.1 HPLC assay 
 
The HPLC assay was a modification of a previous published cefepime 
assay (28). Chromatography was preformed isocratically on an analytical 
reversed-phase Adsorbsphere C18 at 250nm, with 100µg ampicillin as 
internal standard. The mobile phase consisted of 8% v/v acetonitrile in 
20mM ammonium with pH 4.0 The standard curve was calculated in 
quadruples, and inter-day covariation was measured for the three analysis 
days. All the patients samples were injected in duplicates. More HPLC 
assay details are listed in appendix B. 
 
 
3.3.2 Sampling 
 
Blood 
Serial blood samples were taken from the forearm vein contralateral to the 
site of drug administration. Samples were taken right before the dose was 
given and at the following times after completion of the infusion (loading 
dose in those receiving CI): 0, 0.25, 0.5, 2, 4, and 6 hours. In addition, 
blood samples were collected mornings on days 5, 9 and 14 for the CI 
patients. Fresh blood was allowed to clot on ice after sampling before it 
was centrifuged, and then the serum was separated and stored at -70° C 
until assayed.  The catheter that was used to obtain the blood sample was 
flushed with 3mL of 0.9% saline before and after each sample was 
obtained.  In addition, blood samples were obtained as a part of routine 
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care to quantify the erythrocyte sedimentation rate prior to treatment, at 
completion of therapy, and at 1-month follow up. 
 
Urine 
Three 3-mL portions of urine were obtained prior to initiation, at the 
completion of therapy, and at 1-month follow up. The urine samples were 
stored at 70°C until assayed for IL-8 by ELISA. 
 
Sputum 
Sputum samples were obtained after the patient first removed the saliva, 
then coughing up the sputum. If needed, sputum induction using inhaled 
hypertonic saline was used. Samples were obtained prior to initiation, at 
the completion of therapy, and at 1-month follow up. The sputum was 
weighted and admixed with four times the weight of 10% Sputasol® and 
three times the weight with a phosphate buffer solution. Sputasol® is a 
supplement for the liquefaction of sputum samples before microbiological 
testing. This mixture was made homogenous by mixing and then shaking 
at 37°C in a water bath for 5 minutes. This cycle was repeated two 
additional times. The solution was centrifuged at 1000rpm until the pellet 
was solid (about 10minutes). Then the supernatant was separated from the 
pellet and transferred into small vials. The pellet was discarded. The 
supernatant was again centrifuged at 13000 for 15min. This supernatant 
was frozen at -70°C until assayed by ELISA for IL-8 concentration. 
 
Bacterial organism identification was performed by plating on selective 
media according to NCCLS guidelines. Bacterial susceptibility was 
determined using a quantitative disk diffusion assay (E-test, AB Biodisk). 
Sputum bacterial density was determined by plating serially diluted 
sputum samples and counting the colonies using a microscope. The 
sputum bacterial densities were performed by the Microbial Research 
Laboratory at the University of Southern California.  Organism 
identification and in-vitro susceptibility testing were performed at the 
Clinical Microbiology at USC University Hospital. 
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3.3.3 Pharmacodynamic/pharmacokinetic modeling 
 
Pharmacokinetics 
The pharmacokinetic analysis was performed using ADAPT II software 
(Biomedical Simulations Resource, University of Southern California, 
Los Angeles) (38). ADAPT II provides a modeling package for fitting 
concentration data from individuals using a standard two-stage parametric 
approach.  In this study serum concentrations were fitted to both one- and 
two compartment models (see figure 13) using both maximum likelihood 
analysis and the maximum a-posteori  (MAP) Bayesian methods.  
 
 
 
 
 
 
 
 
 
Figure 13: One- and two-compartment models. Left side is the one-
compartment model with the central compartment with volume Vc, and 
clearance CL. The model on the right is the two-compartment model, Vc is 
the volume of the central compartment (1), Vp is the volume of the 
peripheral compartment (2). CLd is the distribution clearance, and CLt is 
the total clearance. R(t) refers to the rate of drug input for both models.  
 
 
The maximum likelihood method fits the curve by minimizing the 
difference between the model estimated concentrations and the observed 
concentration, and calculates the parameters from that model. The MAP 
Bayesian method minimizes the difference between the observed and 
model estimated concentrations, as well as the difference between the 
model-estimated values and the population parameter estimates. This is 
R(t) 
CL 
R(t) 
CLd 
CLt 
Vc 
1
Vc 
2
Vp 
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achieved since MAP-Bayesian starts out with selected mean parameter 
value estimates and their standard deviations as a-priori values. These 
initial values are used as priors to update the parameters using the MAP-
Bayesian algorithm.   
 
The a-priori values for MAP-Bayesian analysis of the 1-compartment 
model were taken from a previous pharmacokinetic study on cefepime 
(24). No previous pharmacokinetic study using a 2-compartment analysis 
has been reported with cefepime, so the a-priori estimates were taken 
from a 2-compartment study on ceftazidime (also adult CF patients) (39), 
a drug that is very similar to cefepime (also se figure 4). The a-priori 
values for both the 1- and 2-compartment models are summarized in 
appendix C.  
 
A fixed linear variance model (variance= 0.1+ 0.1*concentration) was 
used. Model discrimination was based on the generalized information 
criterion (GEN-IC) and the r-squared values for the MAP-Bayesian 
method, and on the Akaike information criterion (AIC) for the maximum 
likelihood method. The pharmacokinetic parameters obtained from this 
analysis were volume of central compartment (Vc) and peripheral 
compartment (Vp), clearance (CL) and distribution clearance (CLd)). 
Using standard equations, distribution half time (t½α) and elimination 
half-life (t½β) were derived.  
 
 
Pharmacodynamics 
The PK/PD parameter time over MIC (T>MIC) has previously been 
shown to be the best parameter to correlate with the antibacterial effect of 
β-lactams (16). To investigate if there is a relationship between the 
PK/PD parameter T>MIC and clinical effect of the treatment, T>MIC was 
compared with the density changes in P. aeruginosa and total bacteria, the 
change in IL-8 concentration, and change in FEV1 from start until end of 
treatment. The pulmonary function marker FEV1 was compared with the 
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decrease in IL-8 concentration. FEV1 is a marker for pulmonary function, 
and IL-8 is a marker for pulmonary inflammation.  
 
The MIC in the PK/PD parameter T>MIC refers to the highest MIC for 
cefepime of all the P. aeruginosa pathogens in the sputum. The time 
above MIC was calculated form the ADAPT data-files using the model 
that best described the serum concentration time course for each patient. 
 
 
3.3.4   ELISA assay 
 
Enzyme linked immunosorbent assay (ELISA) is a very important 
serological test for antigens and antibody (40). The kit used here 
determines IL-8 concentration and is an enzyme amplified sensitivity 
immunoassay (IL-8 EASIA produced by Biosource, Belgium).  
 
The manufacturer already absorbed a specific monoclonal antibody 
directed to bind distinct epitopes of IL-8 onto the 96 wells on the 
microtiter plate. This sensitized the wells to IL-8. Standard or sputum 
sample was added to the wells, allowing the IL-8 and antibody specific 
for IL-8 to react and bind. Next, a monoclonal antibody specific to IL-8 
labeled with horseradish peroxidase was added. A two-hour incubation in 
room temperature and using a horizontal shaker, allowed a sandwich-
formation, consisting of antibody-enzyme, IL-8 and the anchored 
antibody. The microtiter tray was then washed with buffer containing 
preservatives to remove all unbound enzyme linked antibody. To be able 
to measure the IL-8 concentrations a chromogen solution 
(tetrametylbenzidine (TMB) in acetate/citrate buffer with H2O2) was 
added and then the solution was incubated at room temperature for 30min. 
The horseradish peroxidase converts TMB into a colored product. Since 
the horseradish peroxidase was present in the same concentration as IL-8, 
the light density from this solution is proportional with IL-8 
concentration. The absorptions of visible light at 450nm (reference filter 
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at 620nm) were measured with a Tean Spectra. A standard curve was 
made from standard solution provided by the kit from 0-726pg/mL.  
 
The sputum samples were diluted 1:100 (to get the sample concentration 
within the standard curve), and together with the dilution during 
processing, the total dilution of sputum samples was 1:700. Therefore the 
measured concentrations were multiplied by 700 to give correct 
concentration.  
 
 
3.3.5   Statistical methods 
 
The descriptive statistics of the patient population were calculated from 
each subjects age, height, total body weight, BMI, and predicted 
creatinine clearance. Statistical analysis was performed using Graphpad 
Prism version 3.03 (Graphpad Software Inc. San Diego, CA). Differences 
between the clinical measurements from prior to treatment to the end of 
treatment were calculated with paired student-t test. The Mann-Whitney 
nonparametric U-test was used to discriminate between 1- and 2-
compartment models, and a nonparametric t-test was also used to assess 
differences between clinical outcomes and measured parameters. A 
nonparametric student t-test was chosen since the sample size was small 
and will not possess a Gaussian Bell-shaped distribution.  
 
 
3.4 Results 
3.4.1 HPLC assay 
 
The standard curve was linear in the range from 2.5-125µg/mL with a 
correlation factor above 0.999. The recovery from serum was on average 
77.0%. The intraday and interday coefficients of variation ranged from 
2.99-4.90%, and 7.5%. More details from the HPLC-assay are described 
in the appendix B. 
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3.4.2 Pharmacokinetics 
 
A total of eight patients have been enrolled in this study to date. Two 
patients were dropped form the study (one CI and one intermittent), one 
because of nausea and the other due to a pump failure. These two patients 
had serum samples taken, and their PK was calculated, but no clinical 
outcomes were assessed. Of the six patients that completed the study, four 
of them were given intermittent administration and two were given CI. 
The two groups of patients and their demographics and clinical 
parameters are given in table 3, and each patients demographics and 
calculated parameters are shown in a table in  appendix C. 
 
Table 3: Patient demographics of the two groups of patients. The groups 
are divided into CI and intermittent. 
 
Parameter         CI Intermittent      Total Range 
 
Males/Females        1/2        2/3      3/5 
Age (years)     38.0±11       33.0±5   34.9±7.7 26-50  
Height (cm)     166±8.5     171±8.0    169±8.3 158-185 
TBW (kg)     43.4±4.8      64.2±17     56±18 38.4-83.5 
BMI (kg/m2)    16.1±0.8    22.2±4.4    19.9±4.7 15.4-25.8 
CLCR(mL/min)   98.8±44   124.0±21    115±30 58-146 
 
TBW: total body weight, BMI: body mass index, CLCR: creatinine 
clearance (calculated with Cockcroft & Gault) 
 
The PK of cefepime was better described with a two-compartment model 
than with a one-compartment model for both the maximum  likelihood 
and the MAP-Bayesian methods, as shown by the higher r2 values and 
lower AIC and GEN-IC values seen in table 4 and 5, and all the patient 
fittings in figure 14 and 15. There was less bias in the MAP-Bayesian 2-
compartment fitting than in the 1-compartment fitting, as seen in figure 
16. This figure shows the median percent error between the estimated and 
the observed values for each patient. The r-squared was significantly 
better for the two-compartment model (p<0.01, pared two-way t-test) and 
the GEN-IC was significantly higher for the two-compartment model 
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(p<0.03, paired one-way t-test). Patient 3 showed an unreasonable serum 
over time curve, and investigation revealed that there was trouble 
adjusting the pump rate just after initiation of dosing. This patients PK 
was not calculated because of this, but steady state was later achieved and 
PD was calculated. 
 
Table 4: The r-squared and AIC values used in model discrimination 
using a one- or two-compartment mode with maximum likelihood fitting 
model. 
  One-compartment  Two compartment 
Patient  r2 AIC  r2 AIC 
#1  0.819 42.414  0.986 30.885 
#2  0.947 41.608  1.000 32.860 
#4  0.846 48.312  0.977 38.519 
#5  0.950 97.336  0.992 38.589 
#6  0.819 42.414  0.986 30.885 
#7  0.888 100.620  0.976 54.957 
#8  0.872 66.131  0.984 41.747 
 
 
 
 
Table 5: The r-squared and GEN-IC values used in model discrimination 
using a one- or two-compartment MAP-Bayesian model. 
 One-compartment  Two-Compartment 
Patient              r2          GEN-IC  r2            GEN-IC 
#1  0.981 51.342  0.988 42.147 
#2  0.948 38.375  0.986 32.677 
#4  0.841 96.893  0.968 84.009 
#5  0.848 38.847  0.957 42.700 
#6  0.955 93.249  0.990 50.171 
#7  0.819 37.407  0.964 33.586 
#8  0.890 101.00  0.978 73.356 
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Figure 14: Individual serum concentration versus time for the patients 
receiving intermitted dosing. The dashed line represents the 1-compartment 
fitting of the measured concentrations, while the solid line represents the 2-
compartment fitting. The PK of patient #3 were not calculated because of a 
pump rate problem. 
  3.4 RESULTS 
 55
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Boxes and Whiskers of bias in the MAP-Bayesian estimation. 
The figure on the left is for a 1-compartment model and the figure on the 
right is for 2-compartment model. The line is the median percent error in 
the estimation, the boxes are the interquartile intervals, and the whiskers 
are the maximum and minimum values. 
 
Figure 15: Individual serum concentration versus time for the patients 
receiving CI. The dashed line represents the 1-compartment fitting of the 
measured concentration, while the solid line represents the 2-
compartment fitting. #7 has only serum concentration until 6 hours 
because that patient was discontinued from the study. 
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Using the 2-compartment model, all the patients parameters were 
calculated using the MAP Bayesian method. A summary of all the PK 
parameters is shown in table 6.   
 
 
Table 6: PK parameters of the seven patients determined after both 
intermittent and CI cefepime administration using two-compartment 
MAP-Bayesian method.  
Parameter Median Interquartile range 
CLt mL/min/kg) 
CLd(mL/min/kg) 
t1/2α (h) 
t1/2β (h) 
Vc (L/kg) 
Vp (L/kg) 
T>MIC (%)** 
Css,avg(µg/mL) 
Cmax (µg/mL) 
Cmin (µg/mL)               
2.48 
1.91 
0.534 
2.82 
0.314 
0.198 
92.55 
25.30 
137.4 
5.7 
(1.87-2.92) 
(1.28-1.98) 
(0.37-0.62) 
(1.74-4.22) 
(0.27-0.37) 
(0.10-0.25) 
(30.2-100)* 
(24.8-25.8)* 
(111.8-46.2)* 
(2.07-13.2)* 
** Mean T>MIC is only calculated from the intermittent dosing, since all the CI patients 
had T>MIC 100% because of the nature of this administration form. 
* Since the range contains too few patients to give the interquartile range, the range is 
shown as maximum and minimum value.  
CLt : total clearance, CLd: distribution clearance, t1/2α :distribution half-life, t1/2β : 
elimination half-life, Vc: volume of central compartment, Vp: volume of peripheral 
compartment, T>MIC: time above MIC, Css,avg: concentration of steady-state for the 
patients on CI, Cmax: maximum serum concentration, Cmin: minimum serum 
concentration, AUC: area under the serum concentration curve. 
 
 
3.4.3 IL-8 concentrations 
 
The standard curve was linear from 0-726pg/mL (r2>0.98), and according 
to the manufacture the lowest detectible concentration was 0.7pg/mL. The 
CV% from the duplicate standard curve concentrations ranged from 2.5-
13.7%. The control solutions that were provided by the kit were measured 
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to be: the 97pg/mL control was measured to be 109.8±1.2pg/mL (+13% 
compared to control), and 425pg/mL was measured to be 505.9±27pg/mL 
(+19% compared to control). The average CV% from the duplicate 
sample measurements was 6.2%, ranging from 0.9-19.4%. 
 
All the urine samples had too low IL-8 concentration to be measured. 
 
The results from all the sputum samples obtained from the patients who 
completed the study are shown in table 7 and figure 17.  
 
 
 
Table 7: IL-8 concentration in ng/mL in patient sputum taken before 
treatment (0 days), after the end of treatment (14 days), and follow up (1 
month). Nd= not detectable. The thesis was completed before patient 6 
had its 1-month follow-up. 
Patient 0 days 14 days 1 month 
#1 
 
189.3 4.3 33 
#2 nd Nd 2.7 
#3 25.7 3.7 83.5 
#4 161.1 27.7 416.1 
#5 145.8 Nd 28.2 
#6 2.3 4.5  
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Graph 17: IL-8 concentration in ng/mL showed as a function of time after 
started treatment. IL-8 concentrations were measured on three days; 
before treatment (0 days), after treatment (14 days), and follow up 
(1month). 
 
All the patients except one showed a decrease in the IL-8 level during the 
treatment, and an increase after treatment was complete. The IL-8 
concentration showed an average decrease of 45% during the 14 days 
treatment, but this difference was not found to be statistically significant 
(p<0.075, pared t-test, p<0.04 for one-way t-test).  
 
 
3.4.4 Pulmonary function (FEV1) 
 
The average increase in FEV1 during the 14 days treatment was 10% for 
all patients. The improvement in FEV1 during treatment was not 
statistically significant (p<0.15 paired two-way t-test, p<0.05, paired one-
way t-test). All the FEV1 changes are shown in figure 18. 
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Figure 18: Pulmonary function shown as percent predicted FEV1. This 
figure shows the changes in FEV1 in all the 6 patients during the 
treatment (first 14days) and up until the follow up 1month later. All the 
patients showed a increase or the same FEV1 except one patient (#4) 
during treatment (day 0-14). 
 
The patients with the best FEV1 improvement seemed to have a higher 
decrease in IL-8 concentration as shown in figure 19. 
 
Figure 19: Comparing changes in FEV1 with percent changes in IL-8 
concentration. Patients are grouped into two groups; one with an 
increase of >10% in FEV, and those patients that did not achieve 10% 
improvement in FEV1. There are three patients in each group. The line 
represents the median. 
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3.4.5 Bacterial density 
 
To be able to investigate pulmonary bacteria flora, all typical mouth and 
skin bacteria were excluded from the total bacterial count. The six 
patients showed a decrease in bacterial density during the 14 days of 
treatment (p<0.69, two tailed, p<0.35, one tailed, student t-test). The 
decrease in pseudomonas for all patients was minimal. The total bacterial 
density and Pseudomonas density are shown in graph 20: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Both the total bacterial (left) and P. aeruginosa (right) density 
during the treatment is shown with cfu/g sputum on the Y-axis. The 
bacterial count was done on 3 days; before treatment (0d), after treatment 
(14d) and follow-up (30d). 
 
 
There was an indication that a decrease in P. aeruginosa correlated with 
the decrease in IL-8 concentration (p=0.25) as seen in figure 21.  
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Figure 21: Comparing the logarithmic decline in pseudomonas with the 
change in IL-8 concentration. The group of two patients with more than 2 
logarithmic decline of pseudomonas density was compared with a group 
of 4 patients with less than a logarithmic decrease of 2 in pseudomonas 
density with their respective change in IL-8 concentration. The line 
represents the median. 
 
 
Figure 22 shows that there was no correlation between the logarithmic 
decrease of P. aeruginosa and improvement of pulmonary function. The 
result shows that the group with the least change in pseudomonas density 
had a better increase in FEV1, but the difference was not significant. 
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Figure 22: The six patients were divided into two groups, the left group 
had a logarithmic decline of pseudomonas density greater then 2, and the 
group on the right had a logarithmic of pseudomonas density decline of 
less than 2. The two groups were compared with the change in FEV1 on 
the Y-axis. The line is the median. 
 
 
 
 
3.4.6 Time over MIC 
 
The time the serum concentrations were over MIC was 100% for the 
patients receiving CI, for the intermittent patients the average T>MIC was 
92.6%. To investigate the possible correlation between T>MIC and 
clinical effect, the patients were divided into two groups: one with the 3 
patients achieving T>MIC 100% of the time, and the other group that did 
not achieve T>MIC 100% of the time. There were three patients in each 
group. These two groups were then compared with logarithmic decrease 
in both total bacterial and P. aeruginosa density. The group with most 
time over MIC showed a greater decrease in both total bacterial and P. 
aeruginosa density. The comparison is shown in figure 23: 
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Figure 23: The comparison of two groups divided into those patients who 
achieved T>MIC 100% and those that did not and their effect on lowering 
the total bacterial or P. aeruginosa density during the treatment. The 
group that achieved T>MIC 100% of the time showed a higher decline in 
both total bacterial density and P. aeruginosa density. The line represents 
the median. 
 
The same groups were also compared with the ability to lower the IL-8 
concentration in sputum. Figure 24 shows that the group with T>MIC 
100% had a greater decline in IL-8 concentration than the group that did 
not achieve T>MIC 100% (p=0.4). 
 
Figure 24: This figure compares the correlation between the parameter 
T>MIC with the decline in IL-8 concentration. To the left side are the 3 
patients who achieved T>MIC 100%. The points are how much the IL-8 
concentration changed for those patients. To the right are those 3 patients 
who did not achieve T>MIC 100% of the time with their respective 
change in sputum IL-8 concentration on the Y-axis. The line is the median 
of groups.  
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The group with T>MIC of 100% had less improvement in FEV1 than the 
group with T>MIC <100% (p=0.7) as seen in figure 25. 
 
Figure 25: This figure compares the T>MIC with change in FEV1 in 
percent. The three patients with T>MIC 100% of the time are shown at 
the left side and the other three patients are on the right side. The 
patients respective percent changes in FEV1 are shown on the Y-axis. 
The line represents the median. 
 
 
 
3.5 Discussion 
3.5.1 Pharmacokinetics 
 
The maximum likelihood gave a very good fit with respect to the 
measured serum concentrations. But many of the calculated parameters 
had an unlikely value, for example an elimination half-life of 30 hours, 
and peripheral volume of 130L. This is much higher than previous kinetic 
analysis has found with half-life of 2 hours and distribution volume of 
25L (25). This model was rejected and MAP-Bayesian modeling was used 
instead. Since MAP-Bayesian minimizes the sum of errors from the 
measured serum concentrations with the previous populating data, the 
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parameters get a more probable value given that the population 
parameters values are true. All the PK parameters for the individual 
patients are listed in table 9 in appendix C. 
 
The MAP-Bayesian method gave significantly better fitting when 
assuming a 2-compartment model. This was expected since cefepime has 
shown tissue distribution (21). Since this is the first investigation of the 
actual values of the parameters from a 2-compartment model of cefepime, 
the a-posteriors values were taken from a study on ceftazidime (30). 
Figure 16 shows that there was no systematic error in the MAP-Bayesian 
fitting model. The parameters found in this study we similar to two other 
studies on non-compartment cefepime pharmacokinetic (24, 25), and to 
the product information (21), and are summarized in table 8: 
 
 
Table 8: Shows similarities between this study outcome and previous PK 
results. 
Parameter This study Study1 (Arguedas) Study 2 (Huls) Product Info 
Tot Clearance 2.5(ml/min/kg) 3.0±1.5(ml/min/kg) 3.4±1.4(ml/min/kg) 120±8(ml/min/kg) 
Cmax (µg/mL) 137(µg/mL) 141±35(µg/mL)  164±25(µg/mL) 
 
 
To achieve best possible parameter estimates of a 2-compartment model it 
is important to get two or more samples early after the serum 
concentration peak. As seen in figure 14 especially patient #4 and #1 had 
their samples taken late after the peak. This might result in a fitting that 
underestimates the peak concentration and thereby underestimates the 
clearance, as observed in low clearance for both patients #4 and #1.  
 
The ADAPT II software used to calculate the PK values assumes a 
parametric distribution. Since the number of patients was few, parametric 
distribution is not likely. Therefore, median parameter values were 
reported. 
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3.5.2 Pulmonary inflammation 
 
Two other articles have evaluated IL-8 concentrations in CF patients. One 
found that the mean value was 102.4ng/mL, with a 90% range of 63.2-
219ng/mL (41). The other found a mean of 18.0±12.2 ng/mL (42). Both 
these articles show that our measurements were similar to the previous 
found concentrations. The high follow up IL-8 concentration in sputum of 
patient #5 can be explained since the patient also had a high density of 
mucoid Pseudomonas at that time. This is reasonable since inflammatory 
cells produce IL-8 as a result from interaction with the lipid-
polysaccharide (LPS) in P. aeruginosa cell wall.  
 
 
The IL-8 concentration in urine samples was too low to be detected with 
the IL-8 assay kit that was used.   
 
As shown in figure 17 all the patients except one showed a significant 
decrease in IL-8. The one patient that did not have a decrease had a very 
low IL-8 baseline, making improvement difficult. This same patient (#3) 
also had the highest percent-predicted FEV1 at admission, and it is 
possible that this patient did not have a real exacerbation, making it 
difficult to achieve clinical improvement. The rest of the patients showed 
that the inflammation decreases during the treatment; as discussed before 
this can be an indirect effect of a decreasing P. aeruginosa density. 
 
Two patients (#5 and #1) showed an increase in P. aeruginosa and a 
decline in IL-8 concentration. This indicates that the treatment lowers the 
pulmonary inflammation with a different mechanism than just the decline 
in P-aeruginosa density as discussed previously. 
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3.5.3 Pulmonary function 
 
The patients showed an average increase in FEV1 of 10% from admission. 
A previous study with cefepime and clinical improvement in CF patients 
showed an absolute increase of 10% in FEV1 (24, 25). An absolute 
increase of 10% in FEV1 (percent predicted for age and weight) is thought 
to give a clinical difference. None of the patients accomplished a 10% 
absolute increase FEV1. The lower increase in pulmonary function may be 
a result the lower decrease in bacterial density than expected as discussed 
later. 
 
 
3.5.4 Bacterial density 
 
Cefepime is an anti-pseudomonal drug and all the patients except two 
showed a decrease in P. aeruginosa density. The average decrease in 
Pseudomonas density was 44% for 5 of the six patients. However the 
sixth patient (#5) had a large increase in mucoid pseudomonas that draws 
the total average down. One of the patients (#1) that had an increase in 
Pseudomonas density had a high baseline of FEV1 compared with the 
others, indicating the possibility that the patient did not have an 
exacerbation open. The other patient (#5) that did not experience a decline 
in pseudomonas density had a high increase in mucoid Pseudomonas 
during the treatment that could be attributed to potential resistant to 
cefepime. Since the other bacteria were eradicated, it is easier for the 
mucoid strain to grow. In addition the pseudomonas isolate from patient 
#5 was only intermediately susceptible to cefepime. This occurred since at 
admission the most recent susceptibility data was used, this was done 
since susceptibility tests cannot give a rapid result. Since that last 
susceptibility testing the bacteria have become partly resistance to 
cefepime and poor outcome came as expected.  
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A similar relationship demonstrating a decline in total bacterial density 
with time was noted. This was excepted since cefepime exhibits activity 
against gram-negative and gram-positive bacteria. Strains of 
Xanthomonas maltophilia the cefepime exhibited no antibacterial effect; 
however, strains of Staphylococcus aureus, other Pseudomonas strains 
and Nocardia farcinica, were eradicated.  
 
A greater decline in pseudomonas density was expected based on a 
previous study of cefepime that showed a logarithmic decline after 14 
days treatment (24). In addition, cefepime has good bronchial penetration 
(21). One possible explanation is the fact that mucoid P. aeruginosa exists 
within biofilms in patients with CF. Considering the age and severity of 
pulmonary disease in our adult CF population it is possible that a greater 
number of patients in this study were infected with P. aeruginosa within 
biofilms. Traditional in-vitro susceptibility testing is performed on 
planktonic forms of the bacteria that do not correlate well with activity 
against bacterial biofilms. Additionally, these findings could be a result of 
acquired resistance during treatment, and thereby reduced the effect of the 
antibacterial treatment. Increased resistance during treatment has been 
reported previously (24), and in this study no investigation of the 
susceptibility was done after the end of treatment. 
 
The degree of decrease in P. aeruginosa has previously been proven to 
correlate significantly with the degree of improvement in FEV1 (15). A 
similar correlation was not seen in this study, as seen in figure 25. The 
reason could be that this study only had six patients. Additionally, this 
finding could be explained by the fact that the observed decline in 
Pseudomonas density was lower than expected. 
 
This study demonstrated (p<0.25) that the greater decline in pseudomonas 
density resulted in a greater decline in IL-8 concentration after treatment 
was completed, as seen in figure 21. As discussed previously this could 
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have a direct explanation, since IL-8 is produced in response to LPS from 
P. aeruginosa.  
 
 
3.5.5 Time above MIC 
 
The main outcome of this study is whether CI has better clinical effect 
than traditional intermittent dosing. Since only two patients have received 
CI administration to date, patients were dividend into two groups 
regarding the time the serum concentrations were above MIC. One group 
included the patients with time >MIC 100% of the dosing interval, and the 
other group included those that did not. This gave 2 groups with three 
patients in each, since one of the patients (#4) had estimated serum 
concentration above the MIC of 4 mg/mL throughout the dosing interval 
despite receiving intermittent dosing.  
 
The relationship between T>MIC and change in bacterial density is 
depicted in figure 23, which shows that the group with T>MIC 100% had 
a higher decrease in both P. aeruginosa- and total bacterial- densities, 
although the difference was not statistically significant.  The same 
relationship between T>MIC has previously been shown by other 
investigators, as mentioned in the introduction in 1.2.2. The effect 
pseudomonas has on IL-8 concentration was seen in the result in figure 
24, which shows that patients with T>MIC 100% showed a greater 
decline in sputum IL-8 concentration than those with T>MIC <100% of 
the time. The parameter T>MIC did not show any correlation (p<0.7) with 
the pulmonary function seen in FEV1.  It has previous been shown that the 
bacterial density corresponds with pulmonary function (15). The fact that 
a greater T>MIC results in more significant decreases in the pseudomonas 
density can been seen as an indication that patients receiving CI may have 
a better clinical outcome. 
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Previously it has been shown that time over 4 times the MIC correlates 
best with β-lactams effect (43). The reason that T>4*MIC was not used in 
this interim analysis due to the few numbers of patients included in the 
present analysis. 
 
 
3.5.6 Limitations of this study 
 
Since this thesis had a one-year time limit, the data were analyzed before 
all the patients of the study were enrolled. The results showed several 
meaningful trends, however because of small sample size there was no 
statistical significance noted at this time.  
 
The enrollment of patients was slower than expected due to resistant 
bacterial isolates to the cefepime treatment. This led to only eight 
candidates, of which six completed the study. The nature of the 
randomization of the drug administration gave only two patients with CI 
and four receiving intermittent administration.  
 
 
 
3.6 Conclusions and future directions 
 
Cefepime was best described using a 2-compartment model. MAP-
Bayesian estimation provided parameter values consistent with previous 
reports.  
 
The marker for inflammation, IL-8, had too low of a concentration in 
urine to be detected. In sputum the IL-8 concentration was much higher, 
and IL-8 concentration decreased during treatment. This decrease in 
inflammation can be explained the reduction in P. aeruginosa density.   
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CI has the advantage over intermittent dosing by achieving time over MIC 
100% of the dosing interval. This study had too few patients to be able to 
make definitive conclusions; however, it appears that maximizing T>MIC 
resulted in greater antibacterial effects. This was seen by the greater 
reduction in bacterial load, and inflammatory mediators in patients who 
sustained serum concentrations above the MIC throughout the dosing 
interval. Obviously since CI will always have higher T>MIC than 
intermittent, this could be seen as an indication that CI is more effective 
administration way for cefepime and possible other β-lactams. 
 
Later when more patients are enrolled, the same tests can be used and 
provide much higher significance, and perhaps more powerful 
conclusions can be drawn.  
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V. APPENDIX A: STABILITY TESTING; HPLC ASSAY AND 
EQUIPMENT 
 
HPLC assay 
The intra-day coefficient of variation, measured with triplicates, ranged 
from 0.05%-1.15%, and inter-day during the 23 analytical days ranged 
from 1.33%-3.48%. 
Cefepime was eluted after 7.8-8.6 minutes. The assay lower part of the 
standard curve was 25µg/mL. At this concentration the coefficient of 
variation was 0.54%. 
 
None of the degradation products interfered with the cefepime peak, as 
shown in figure 26: 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC equipment: 
Pump: Hitachi, L-6200 Intelligent pump. 
Detector: Hitachi, L-4200, UV-VIS Detector. 
Autosampler: Hitachi AS-2000. 
Integrator: Hitachi D-2500 Chromato-integrator. 
Recycler: Alltech. 
Figure 26: On the top is the chromatogram of freshly made cefepime 
solution, on the bottom is 9.7% of the cefepime broken down, and 
degradation products (retention time 3-6min) has no interference 
with the cefepime area. 
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Column: C-18 column (250x4.6mm) with 4.6µm diameter particles from 
J&W Scientific. 
 
Mass spectrometry: 
Micromass Quattro Ultima triple quadrupole tandem mass spectrometer 
(Micromass, Beverly, MA). 
 
Chemicals: 
Cefepime: Maxipime from Elan. Lot 1A42352, 0M28658 and 1F37831. 
Sterile dextrose 5% from Abbott laboratories. 
Ammonium Acetate, HPLC grade from Fisher Chemical. 
Acetonitrile, HPLC grade from EM science. 
Acetic acid, HPLC grade from J.T Baker. 
0.2 µm 47mm nylon membrane filters from Gelman sciences. 
0.2 µm 4mm nylon membrane filters from Nalgene. 
 
Continuous infusions equipment: 
Portable infusion pump: Microject 30, made of Sorensen Medical, West 
Jordan UT.  
Drug reservoir and waste bag: MediBag, made of EVA, 250mL from 
Sorenson medical. 
Microject cassette: filter, from Sorenson medical. 
McGaw HyperFormer® PCA mixing container 250mL. 
Black belt bag for the pump, drug reservoir and waste bag. 
 
Temperature measurement: 
TempTrace, electronic temperature reader from Dickson. 
Software for TempTrace; DicksonWare for windows V2.2LC. 
 
Other: 
Waterbath from Precision Scientific Co. 
pH-meter type 320 from Corning 
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VI. APPENDIX B: HLPC ASSAY FOR SERUM SAMPLES AND 
EQUIPMENT 
 
HPLC-assay 
The serum processing consisted of adding 200µL of acetronitrile to the 
serum, then vortexing the mixture and centrifugation at 14000rmp for 
15min. This step was done to precipitate and separate proteins in serum. 
The supernatant was then evaporated to dryness and reconstituted into 
500µL of water. 50µL of this solution was injected into the HPLC. The 
mobile phase consisted of 8% v/v acetonitrile in 20mM ammonium 
acetate, adjusted to pH 4.0 with glacial acetic acid, all HPLC grade 
quality. The mobile phase was filtrated through a 47mm 0.22µm nylon 
membrane filter before use. To accomplish less interference from serum 
components, cefepime was detected at 250nm instead of its peak 
absorption at 260nm (29). The internal standard, ampicillin, was chosen 
because of its similar structure with cefepime and because of its 
availability. Ampicillin had a much lower absorption at 250nm and 100µg 
ampicillin was added to each solution to get absorption similar to the 
middle range of the standard curve. The co administration of Tobramycin 
has low or no UV absorption (44), and did not interfere with the 
determination of cefepime and ampicillin. 
 
After each sample containing serum, the HPLC was washed for 10 
minutes with acetonitrile to remove any possible compounds form serum 
that might be plugged in the column. Then it was flushed 10 minutes with 
the mobile phase to get the system homogenous again.  
The standard curve is shown in figure 27. 
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Standard curve of cefepime in serum
y = 24.815x + 0.0929
R2 = 0.9993
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Figure 27: The standard curve of cefepime in serum: The peak height  
between cefepime and the internal standard ampicillin is plotted on the x-
axis and the belonging cefepime concentrations are on the y-axis. 
 
A typical patients chromatogram is shown in figure 28. 
 
Figure 28: A typical chromatogram. Cefepime is eluted in 9.5 minutes 
with baseline separation from serum components with retention time 1-
8minuts and also baseline separation with the internal standard 
(ampicillin) with retention time 12.5 minutes. 
 
HPLC equipment: 
Pump: Perkin-Elmer series 410 LC pump. 
Detector: Perkin-Elmer, LC 90 UV, spectrophotometric detector. 
Autosampler: Waters 715 Ultra WISP sample processor. 
Column: Alltech Adsorbsphere C18 250x 4.6mm. 
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Chemicals: 
Cefepime: Analytical grade lot. no 1C42905L from Bristol-Myers Squibb. 
Ampicillin: Analytical grade lot.no.60120 from Bristol-Myers Squibb. 
Ammonium Acetate, HPLC grade from Fisher Chemical. 
Acetonitrile, HPLC grade from EM science. 
Acetic acid, HPLC grade from J.T Baker. 
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VII. APPENDIX C: PHARMACOKINETIC PARAMETERS  
 
A-priori values: 
For the 1-compartment MAP-Bayesian modeling (24):  
Total body clearance: 3.01±1.46 mL/min/kg 
Volume of distribution: 0.32±0.10L/kg 
 
For the 2-compartment MAP-Bayesian modeling (39): 
Distribution half life: 0.38±0.18 h 
Elimination half life: 1.84±0.76 h 
Volume of central compartment: 0.19±0.03 L/kg 
Total body clearance: 8.74±1.86 L/h 
Volume of peripheral compartment and distribution clearance was 
calculated using these parameters. 
Patients demographics and parameters calculated with a 2-
compartment MAP-Bayesian model: 
 
Table 9: 1*= DF508, Clearance was calculated with Cockroft & Gault 
equation. IM: Intermittent, PK: Pharmacokinetics, Patient #3 had flow 
rate problems and PK parameters were not calculated. 
Patient # 1 2 3 4 5 6 7 8 
Genotype 1*/1* 1*/R117H 1* 1*/D11528 N1303K 1*/W1282X 1*/1*  
Dose IM(PK only) IM CI(PK only) IM CI IM CI IM 
Age 26 36 50 38 36 37 28 28 
Height (cm) 165 170 158 170 165 185 175 163 
Weight (kg) 48.8 71.8 38.4 72.4 44.9 83.5 47 44.6 
BMI(kg/m2) 17.9 25.59 15.4 25.81 17 25.07 15.93 16.8 
CrCl(mL/min) 131 110 58 147 92 133 146 99 
Adm FEV1 53%, 1.67 26%, 0.65 61%, 1.92 70%, 2.18 38%, 1.77 23%, 0.82 44%, 1.28 23%, 0.98
CLt (L/h) 
CLd (L/h) 
T1/2 α (hour) 
T1/2 β (hour) 
Vc (L) 
Vp (L) 
T>MIC(%) 
AUC 
Cavg,ss(µg/mL) 
Cmax(µg/mL) 
Cmin(ug/mL)  
2.480 
1.278 
0.367 
1.738 
0.271 
0.104 
88.000 
 
- 
137.420 
2.060  
1.870 
1.293 
0.386 
1.897 
0.271 
0.092 
30.200 
 
- 
146.240 
3.982  
 
 
100 
 
 
 
 
  
1.540 
1.158 
0.668 
4.216 
0.414 
0.198 
100.000 
 
- 
111.820 
10.140  
2.579 
1.976 
0.581 
3.276 
0.370 
0.245 
100.000 
 
25.800 
- 
-  
3.368 
1.925 
0.534 
2.819 
0.329 
0.249 
97.1% 
 
- 
127.990 
5.679  
2.920 
2.333 
0.320 
1.644 
0.214 
0.125 
- 
 
24.800 
- 
-  
2.217 
1.908 
0.620 
6.608 
0.314 
0.528 
- 
 
- 
141.930 
13.195  
  VIII. REFERANCES 
 78
VIII. REFERENCES 
 
 
1. Wine, J. J. (1999). "The genesis of cystic fibrosis lung disease. 
Journal of Clinical Investigation 103: 309-312. 
2. Foundation, C. F. (2000). "Patient Registry 2000 Annual Report, 
Bethesda, Maryland. 
3. Welsh, M. J., and Smith, A. L. (1995). "Cystic Fibrosis. Scientific 
American 273: 52-59. 
4. Davis, P. B., Drumm, M., and Konstan, M. W. (1996). "Cystic 
Fibrosis. State of the Art 154: 1229-1256. 
5. Beringer, P. (2000). "Textbook of Theraputics. (Herfindal, E., 
and Gourley, D., Eds.), Lippincott Williams & Wilkins. 781-795 
6. Rommens, J. M., Iannuzzi, M. C., Kerem, B., Drumm, M. L., 
Melmer, G., Dean, M., Rozmahel, R., Cole, J. L., Kennedy, D., 
and Hidaka, N. (1989). Identification of the cystic fibrosis gene: 
chromosome walking and jumping. Science 245: 1059-1065. 
7. Gabriel, S. E., Bringman, K., Koller, H., Boucher, R., and Stutts, 
J. (1994). "Cystic Fibrosis Hetrozygote Resistance to Cholera 
Toxin in Cystic Fibrosis Mouse Model. Science 266: 107-109. 
8. Doull, I. J. (2001). "Recent advances in cystic fibrosis. Archives 
of Disease in Childhood 85: 62-66. 
9. Stutts, M. J., Rossier, B. C., and Boucher, R. C. (1997), "Cystic 
fibrosis transmembrane conductance regulator inverts protein 
kinase A-mediated regulation of epithelial sodium channel single 
channel kinetics. Journal of Biological Chemistry 272: 14037-
14040. 
10. Knowles, M. R., Stutts, M. J., Spock, A., Fischer, N., Gatzy, J. T., 
and Boucher, R. C. (1983). "Abnormal ion permeation through 
cystic fibrosis respiratory epithelium. Science 221: 1067-1070. 
11. Davis, P. B., Hubbard, V. S., and Di Sant'Agnese, P. A. (1980). 
"Low sweat electrolytes in a patient with cystic fibrosis. 
American Journal of Medicine 69: 643-646. 
  VIII. REFERANCES 
 79
12. Desmond, K., Schwenk, W., Thomas, E., Beaudry, P., and Coates, 
A. (1983). "Immediate and long-term effects of chest 
physiotherapy in patients with cystic fibrosis." Journal of 
Pediatrics 103: 538-542. 
13. Ramsey, B. W. (1996). "Drug Therapy: Management of 
Pulmonary Disease in Patients with Cystic Fibrosis. The New 
England Journal of Medisine 335(3): 179-188. 
14. Shak, S., Capon, D., Hellmiss, R., Marsters, S., and Baker, C. 
(1990). "Recombinant human DNase I reduced the viscosity of 
cystic fibrosis sputum. Proceedings of the National Academy of 
Sciences of the United Stats of America. 87: 9188-9192. 
15. Regelmann, W. E., Elliott, G. R., Warwick, W. J., and Clawson, 
C. C. (1990). "Reduction of sputum Pseudomonas aeruginosa 
density by antibiotics improves lung function in cystic fibrosis 
more than do bronchodilators and chest physiotherapy alone. 
American Review of Respiratory Disease 141: 914-921. 
16. Craig, W. A. (1998). "Pharmacokinetics/Pharmacodynamic 
Parameters: Rationale for Antibacterial Dosing on Mice and 
Men. Clinical Infectious Diseases 26: 1-26. 
17. MacGowan, A. P., and Bowker, K. (1998). "Continuous Infusion 
of Beta-Lactam Antibiotics. Clinical Pharmacokinetics 35: 391-
402. 
18. Vondracek, T. G. (1995). "Beta-Lactam antibiotics: Is continuous 
infusion the preferred method of administrations?" Infectious 
Disease 29: 415-423. 
19. Tessier, P. R., Nicolau, D. P., Onyeji, C., and Nightingale, C. H. 
(1999). "Pharmacodynamics of Intermittent- and Continuous-
Infusion Cefepime Alone and in Combination with Once-Daily 
Tobramycin against Pseudomonas aeruginosa in an in vitro 
Infection Model. Chemotherapy 45: 284-295. 
20. McNabb, J., and Khanh, Q. B. (2002). "Antimicrobial 
Pharmacodynamics in Theory and Clinical Practice. 
(Nightingale, C. H., Ed.), Marcel Drekker Inc, New Tork. 99-123 
  VIII. REFERANCES 
 80
21. Elan. (2000). Maxipime Product information. Elan, San Diego, 
CA. 
22. Kessler, R. E. (2001). "Cefepime microbiologic profile and 
update. SO - Pediatric Infectious Disease Journal. 20(3): 331-
336.  
23. American Society of Health-System Pharmacicts. (1996). 
"Cefepime Hydrochloride. Web: www.ashp.org 
24. Arguedas, A. G., Stutman, H. R., Zaleska, M., Knupp, C. A., 
Marks, M. I., and Nussbaum, E. (1992). "Cefepime. 
Pharmacokinetics and clinical response in patients with cystic 
fibrosis. American Journal of Diseases of Children 146: 797-802. 
25. Huls, C. E., Prince, R. A., Seilheimer, D. K., and Bosso, J. A. 
(1993). "Pharmacokinetics of cefepime in cystic fibrosis patients. 
Antimicrobial Agents & Chemotherapy 37: 1414-1416. 
26. Fubara, J. O., and Notari, R. E. (1998). "Influence of pH, 
temperature and buffers on cefepime degradation kinetics and 
stability predictions in aqueous solutions. Journal of 
Pharmaceutical Sciences 87: 1572-1576. 
27. Viaene, E. (2002). "Comparative Stability studies of 10 
antipseudomonal beta-lactams for Potential Administation by 
Continuous Infusion to Cystric Fibrosis and Intensive Care 
Patients". Antimicrobial Agents & Chemotherapy 46(8): 2327-
2332 
 Antimicrobial Agents & Chemotherapy. 46(8): 2327-2332 
28. Elkhaili, H., Linger, L., Monteil, H., and Jehl, F. (1997). "High-
performance liquid chromatografic assay for cefepime in serum. 
Journal of Chromatografy B 690: 181-188. 
29. Ip, M., Au, C., Cheung, S. W., Chan, C. Y., and Cheng, A. F. 
(1998). "A rapid high-performance liquid chromatographic assay 
for cefepime, cefpirome and meropenem. Journal of 
Antimicrobial Chemotherapy 42: 121-123. 
30. Vinks, A. A. T. M. M. (1994). "Pharmacokinetics of Ceftazidime 
in Adult Cystric Fibrosis Patients During Continuous Infusion and 
  VIII. REFERANCES 
 81
Ambulatory Treatment at Home. Therapeutic Drug Monitoring 
16: 341-348. 
31. Hamelin, B. A., Moore, N., Knupp, C. A., Ruel, M., Vallee, F., 
and LeBel, M. (1993). "Cefepime pharmacokinetics in cystic 
fibrosis. Pharmacotherapy 13: 465-470. 
32. Florence, A. T., and Attwood, D. (1998). "Physiochemical 
principles of Pharmacy", MacMillan Press LTD, London. 101-150 
33. Fubara, J. O., and Notari, R. E. (1997). "A Kinetic Oxymoron: 
Concentration-Dependent First-Order Rate Constants for 
Hydrolysis of Ceftazidime. Journal of Pharmaceutical Sciences 
87: 53-57. 
34. Servais, H., and Tulkens, P. M. (2001). "Stability and 
Compatibility of Ceftazidime Administered by Continuous 
Infusion to Intensive Care Patients. Antimicrobial Agents & 
Chemotherapy 45: 2643-2647. 
35. Williamsen, J., Volles, D., Lynch, P., Rogers, P., and Haverstick, 
D. (1999). "Stability of cefepime in peritoneal dialysis solution. 
Annals of Pharmacotherapy 33: 906-909. 
36. Sugioka, T., Asano, T., Chikaraishi, Y., Suzuki, E., Sano, A., 
Kuriki, T., Shirotsuka, M., and Saito, K. (1990). "Stability and 
degradation pattern of cefpirome (HR 810) in aqueous solution. 
Chemical & Pharmaceutical Bulletin 38: 1998-2002. 
37. Trissel, L. A., Martinez, J. F., and Simmons, M. (1999). 
"Compatibility of etoposide phosphate with selected drugs during 
simulated Y-site injection. Journal of the American 
Pharmaceutical Association 39: 141-145. 
38. D'Argenio, D. Z., and Schumitzky, A. (1997). Userguide in 
ADAPT II, Biomedical Simulations Resource, Los Angeles, CA, 
USA. 
39. Vinks, A. A. T. M. M. (1996). Rijksuniversiteit Leiden, Haag. 64-
65 
40. Prescott, L. M., Harley, J. P., and Klein, D. A. (1999). 
"Microbiology", McGraw-Hill, Bosten. 666-668 
  VIII. REFERANCES 
 82
41. Suri, R., Marshall, L. J., Wallis, C., Metcalfe, C., Bush, A., and 
Shute, J. K. (2002). "Effects of Recombinant Human DNase and 
Hypertonic Saline on Airway Inflammation in Children with 
Cystic Fibrosis. American journal of Respiratory and critical 
care medicine 166: 352-355. 
42. Henig, N. R., Tonelli, M. R., Pier, M. V., Burns, J. L., and Aitken, 
M. L. (2001). "Sputum induction as a research tool for sampling 
the airways of subjects with cystic fibrosis. Thorax. 56: 306-311. 
43. Tam, V. H., McKinnon, P. S., Akins, R. L., Rybak, M. J., and 
Drusano, G. L. (2002). "Pharmacodynamics of cefepime in 
patients with Gram-negative infections. Journal of Antimicrobial 
Chemotherapy 50: 425-428. 
44. Lai, F., and Sheehan, T. (1992). "Enhancement of detection 
sensitivity and cleanup selectivity for tobramycin through pre-
column derivatization. Journal of Chromatography  609: 173-
179. 
 
